Introduction {#s1}
============

Vertebrate skeletal and cardiac muscles produce force through a chemo-mechanical cycle that contracts and relaxes the sarcomere, the contractile unit in all muscle cells. Sarcomeres are composed of inter-digitating thick filaments that contain myosin, comprising a globular head (subfragment 1; S1) and α-helical tail, and thin filaments that contain actin. Interactions between myosin and actin generate the contractile force underpinning sarcomere contraction.

Myosin heads comprise a motor domain (MD) that hydrolyses ATP, a regulatory domain (RD) that includes the essential (ELC) and regulatory (RLC) light chains, and a proximal S2 subfragment. Myosin tails are packed in antiparallel formation and shape the thick filament's backbone, from which myosin heads protrudes every 14.3 nm as crowns formed by three pairs of heads. In some crowns ([@bib80]) the S2 fragment interacts with myosin binding protein-C (MyBP-C), another thick filament protein that modulates sarcomere activity. Contraction occurs through conformational changes in the myosin MD that accompany ATP hydrolysis, increasing affinity for actin in the thin filament, and resulting in a powerstroke that transfers force by rotation of the myosin lever domain around the converter domain.

After contraction, myosin heads rebind ATP, detach from actin, and assume a relaxed pre-powerstroke state ([@bib43]). During relaxation, two myosin heads pack together to form an interacting-heads motif (IHM; \[[@bib74]\]). Consecutive IHMs interact along helices that protrude from the thick filament backbone and limit potential interactions between myosin heads and actin ([@bib4]; [@bib31]). The IHM forms only in relaxed muscle and is a highly conserved structure throughout the evolution of myosins among different species, in different muscle types (smooth, skeletal, and cardiac), and non-muscle myosins ([@bib3]).

The IHM appears to form through key interactions ([Figure 1A](#fig1){ref-type="fig"}) involving the actin-binding region of one myosin head (denoted as 'blocked') and the converter region of the partner 'free' head ([@bib74]; [@bib4]; [@bib31]). IHM priming occurs when the blocked head assumes a pre-powerstroke state ([@bib43]) and docks onto its own S2 by intra-molecular interactions. IHM anchoring occurs by inter-molecular interactions between the docked, blocked head and the neighboring myosin's tail, and intra-molecular interactions with its ELC. IHM stabilization occurs by intra-molecular interactions between the free myosin head and the anchored blocked head ([@bib4]; [@bib9]; [@bib3]). IHM scaffolding interactions between myosin heads and both ELCs and RLCs further support its three-dimensional shape.10.7554/eLife.24634.002Figure 1.The molecular pathogenesis of hypertrophic (HCM) and dilated (DCM) cardiomyopathy assessed in the context of the myosin interacting-heads motif (IHM) paradigm.Myosin interactions involved in IHM assembly and myosin motor domain (MD) functions that are altered by PVs and LPVs are depicted. (**A**) Relaxed healthy cardiac muscle contains myosin heads populations in the super-relaxed (SRX) state (left) with lowest ATP consumption and a disordered relaxed (DRX) state (right) with swaying free heads that generate force with higher ATP consumption. The population of cardiac myosins in SRX is more stable than in skeletal muscle ([@bib27] and see Material and methods) which supports physiologic contraction and relaxation, energy conservation, and normal cardiac morphology. (**B**) HCM myosin variants both alter residues involved in MD functions (causing increased biophysical power \[[@bib69]\]), and destabilize IHM interactions (particularly those with altered electrostatic charge). Reduced populations of myosins in the SRX state and increased populations of myosins in DRX as well as enhanced MD properties will result in increased contractility, decreased relaxation, and increased ATP consumption, the three major phenotypes observed in HCM hearts. Compensatory signals may promote ventricular hypertrophy. (**C**) *MYH7* DCM variants have modest effects on IHM interactions but substantially reduce MD functions, particularly nucleotide binding, resulting in reduced ATP consumption and sarcomere power ([@bib56]), with minimal impact on relaxation and overall diminished contractility. Compensatory signals result in ventricular dilatation to maintain circulatory demands in DCM hearts.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.002](10.7554/eLife.24634.002)

The dynamic structure of the IHM ([@bib9]) enables properties that are not observed in isolated S1 myosin fragments ([Figure 1A](#fig1){ref-type="fig"}): (i) reduced ATPase activity in blocked heads and intermittently in the free head; (ii) mobility of the free head, that sways forth and back by breaking and restoring stabilizing IHM interactions ([@bib4]; [@bib9]; [@bib65]; [@bib16]; [@bib2]; [@bib76]; [@bib3]); and (iii) release of extra free heads upon activation and blocked heads for force potentiation ([@bib9]). Consistent with these properties, negatively stained smooth muscle myosins show that free heads are flexible, detaching from their partner blocked heads and adopting different motor domain orientations ([@bib10]); that swaying free heads support the sliding of F-actin filaments along relaxed thick filaments ([@bib9]); and that thick filament respond to calcium activation producing force immediately ([@bib41]).

The asymmetric IHM structure imposes functional consequences on the sarcomere. The blocked myosin head has a pre-powerstroke state ([@bib75]; [@bib79]; [@bib43]) while docked onto its S2, so ATPase activity is sterically inhibited, and the actin-binding interface is positioned on the converter domain of the free head, so that it cannot bind actin. By contrast, the partnered free myosin head can sway, hydrolyze ATP, and bind actin, producing disordered relaxation (DRX; \[[@bib46]\]). In addition, the asymmetric conformations of myosins could also impact RLC phosphorylation, which modulates the rate and extent of force development in cardiac muscle ([@bib68]). The RLC associated with the free head is more accessible to protein kinase C phosphorylation ([@bib4]), which promotes swaying ([@bib9]) and potential actin interactions.

The IHM structure could account for super-relaxation (SRX; \[[@bib64]\]). When the free myosin head docks onto the blocked head, its ATPase is also inhibited through stabilization of converter domain movements that are needed to achieve strong actin binding ([@bib73]). The dual enzymatic inhibition of SRX is reflected by a low ATP turnover rate, detected by quantitative epi-fluorescence in skeletal ([@bib64]; [@bib48]; [@bib46]) and cardiac ([@bib27]) relaxed muscle fibers, and is proposed as an energy saving mechanism ([@bib13]). Muscle relaxation can therefore be characterized by two myosin head IHM conformations and ATPase activities ([Figure 1A](#fig1){ref-type="fig"}): the DRX state with swaying free myosin heads and ATPase rate comparable to that observed in single myosin molecules, and the SRX state with a highly inhibited (five-fold lower) ATPase rate ([@bib64]; [@bib48]; [@bib46]; [@bib27]).

Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are heart muscle diseases caused by variants in genes encoding sarcomere proteins ([@bib18]; [@bib58]; [@bib34]), most commonly *MYH7* (encoding cardiac β-myosin heavy chain; MHC) and *MYPBC3* (encoding MyBP-C) and rarely in *MYL2* and *MYL3* that encode the ELC and RLC, respectively. Distinct variants in sarcomere genes also cause DCM, albeit less frequently. Variant location is not highly predictive of whether it will trigger HCM or DCM ([@bib12]).

HCM hearts exhibit hyperdynamic contraction, impaired relaxation, and increased energy demands ([@bib6]). Impaired relaxation (clinically denoted as diastolic dysfunction) is a major cause of HCM symptoms and arrhythmias. Increased energy demands in HCM hearts are thought to contribute to cardiomyocyte death and progression to heart failure. Previous studies demonstrate that HCM *MYH7* variants increase myofibrillar Ca^2+^-sensitivity and sarcomere power, therein explaining hyperdynamic contraction ([@bib59]; [@bib69]; [@bib47]; [@bib62]; [@bib45]; [@bib24]; [@bib6]; [@bib61]), but the mechanisms accounting for diminished relaxation and excessive energy requirements remain poorly understood. By contrast, DCM *MYH7* variants decrease Ca^2+^-sensitivity and reduce motor domain functions ([@bib15]; [@bib47]; [@bib62]; [@bib45]; [@bib61]), therein accounting for diminished contractile performance, the prototypic feature of DCM. Unlike HCM, diastolic dysfunction is uncommon early in the clinical course of DCM ([@bib37]) but emerges with myocardial remodeling.

Disease-associated *MYH7* variants cause single amino acid (aa) substitutions, and as such the locations of these substitutions inform physiologically important domains in myosin. Because myosin sequences are highly conserved across species, the impact of *MYH7* variants on MD properties have been studied in the context of a variety of vertebrate molecular myosin structures. Early analyses, employing the chicken skeletal S1 myosin ([@bib53], [@bib54]), demonstrated that HCM variants perturbed MD residues involved in nucleotide-binding, actin-binding, or the relay, converter, and lever. More recently additional HCM variants were located onto the myosin mesa ([@bib26]), a newly characterized flat broad (\>20 nm^2^) structural feature that is proposed to bind MyBP-C ([@bib63]; [@bib61]). The mesa is prominent in the pre-stroke S1 contractile state, but substantially reduced following the powerstroke ([@bib26]).

The tarantula striated IHM quasi-atomic model PDB 3DTP ([@bib4]) complements these structures by defining interactions between adjacent myosin heads and possible interactions with IHM-associated protein partners and the backbone. Harnessing this model with other structures (human S2 crystal PDB 2FXM model \[[@bib8]\] and chicken smooth muscle myosin PDB 1I84 model \[[@bib42]\]), the analyses of a few selected HCM variants ([@bib8]; [@bib4]; [@bib47]) hint that these may impact residues involved in IHM intra- and intermolecular interactions.

Here we assessed the structural pathogenesis of HCM and DCM by comprehensive analyses of the largest series of genotyped cardiomyopathy cases, comprising 7427 individuals with clinical-grade sequencing ([@bib70]). Modeling a human homologous β-cardiac myosin IHM model (PDB 5TBY, newly reported here) to the newest tarantula IHM quasi-atomic structure PDB 3JBH ([@bib3]), we first identified putative interaction sites, then examined the locations of all variants categorized as pathogenic (PVs) and likely pathogenic (LPVs) in *MYH7*, *MYL2*, and *MYL3*. We demonstrate that HCM and DCM variants differentially impact myosin MD functions and specific IHM interactions, data that informs the mechanisms for failed contractile power in DCM and the markedly compromised relaxation and energetics in HCM ([@bib7], [@bib6]).

Results {#s2}
=======

Human β-cardiac myosin IHM quasi-atomic PDB 5TBY model to identify interaction sites {#s2-1}
------------------------------------------------------------------------------------

We modeled a homologous human β-cardiac myosin IHM structure ([Figure 2A](#fig2){ref-type="fig"} and [Video 1](#media1){ref-type="other"}; deposited as entry PDB 5TBY) based on the tarantula striated muscle IHM quasi-atomic cryo-EM structure (PDB 3JBH, [@bib3]; Materials and methods). Although resolution of the IHM structure as derived by cryo-EM does not define specific atomic contacts or individual side chain densities, this model nonetheless identifies molecular interactions.10.7554/eLife.24634.003Figure 2.Structure of the human β-cardiac myosin interacting-heads motif.(**A**) Quasi-atomic homologous model of human β-cardiac myosin interacting-heads motif (IHM) PDB 5TBY composed of blocked (BH) and free (FH) heads, fitted to the human cardiac thick filament 3D-map EMD-2240 ([@bib1]). (Also see [Video 1](#media1){ref-type="other"}.) Domains and residue equivalence are provided in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Sarcomere proteins depicted are MHC (BH: gold, FH: olive), essential light chain (ELC associated with BH: brown, FH: purple), and regulatory light chain (RLC associated with BH: dark blue, FH: blue). The three negatively-charged rings in the S2 are labeled R1, R2 and R3. (**B**) Calculated small angle X-ray solution scattering (SAXS) profile of PDB 5TBY (red line) matches the experimental squid heavy meromyosin SAXS profile (green dots) ([@bib19]). Integrated scattering intensity (I in arbitrary units) is given as a function of momentum transfer, q = 4π sin(θ)/λ, with a scattering angle of 2θ and a wavelength of λ. (**C**) Relative deviation between PDB 5TBY scattering and squid HMM (red line) is calculated as (I~model~-I~exp~)/I~exp~. The corresponding difference in scattering between PDB 5TBY and PDB 3JBH models is also shown on the same scale (black dashed line). Comparison shows that the models cannot be distinguished based on currently available scattering data (See Supplementary Figures).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.003](10.7554/eLife.24634.003)10.7554/eLife.24634.004Figure 2---figure supplement 1.Calculated small angle X-ray solution scattering (SAXS) profile of PDB 5TBY (red line) matches experimental squid heavy meromyosin (HMM) SAXS profile (green dots) ([@bib19]).The comparison of model-based tarantula PDB 3JBH (blue dashed line) vs. human cardiac ventricular IHM PDB 5TBY (red line) scattering with measured squid HMM scattering profiles (green dots) in (**A**) shows that the models cannot be distinguished based on the scattering data that is currently available. Computations are performed using the FoXS algorithm ([@bib57]) using the default parameters of hydration layer, excluded volume, and background adjustment ([@bib19]). In the case of (**A**) the 'profile offset' optimization was performed to obtain best fit with the data at widest angles. The predicted scattering profiles are based on electron microscopy-derived striated tarantula muscle PDB 3JBH ([@bib3]) (blue dashed line) IHM models. Calculated wide-angle scattering data (**B**), computed without reference to the squid HMM profile, confirms that the models do not significantly differ in the wide angle X-ray solution scattering (WAXS) region.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.004](10.7554/eLife.24634.004)10.7554/eLife.24634.005Figure 2---figure supplement 2.Wide-eye stereo pairs that compare the PDB 5TBY model with crystal structures of fragments for human β-cardiac S1 MD fragment (PDB 4DB1) and S2.(**A**) Superimposed MDs of S1 from the PDB 5TBY antavd a S1 fragment of human β-cardiac myosin S1 crystal structure PDB 4DB1 (AMPPNP rigor-like structure) See [Video 2](#media2){ref-type="other"}. Color code: PDB 5TBY: Blocked head (gold), free head (FH) (olive); PDB 4DB1: blocked head (brown), free head (magenta). All chains are shown as wires with the interacting loops highlighted as ribbons. (**B**) Superimposed S2 from the PDB 5TBY (same color code as A) and the S2 of the human β-cardiac myosin S2 (pink) crystal structure PDB 2FXM ([@bib8]) See [Video 3](#media3){ref-type="other"}. (**C**) Free and blocked head structures of PDB 5TBY vs. PDB 1BR1 structures (See [Video 4](#media4){ref-type="other"}). The free and blocked head MDs of PDB 5TBY (same color code as A) fits well the pre-powerstroke PDB 1BR1 crystal structure (magenta). The ELC and RLC were removed to highlight their lever arms, which are in the same plane but have different angles.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.005](10.7554/eLife.24634.005)Video 1.A homologous human β-cardiac myosin IHM structure.The PDB 5TBY IHM model is initially depicted as a ribbon structure that includes paired myosin heads (blocked head (BH), gold, free head (FH), olive), essential light chain (ELC associated with BH: brown, FH: purple), and regulatory light chain (RLC associated with BH: dark blue, FH: blue). The PDB 5TBY IHM model is then fitted into the human cardiac thick filament (3D-map EMD-2240; A([@bib1]) as detailed in Materials and methods. See legend of [Figure 2A](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.006](10.7554/eLife.24634.006)10.7554/eLife.24634.006

### Comparisons of the human β-cardiac myosin IHM quasi-atomic PDB 5TBY with existing models {#s2-1-1}

The new model fitted well to the 28 Å resolution 3D-reconstruction for the negatively stained human cardiac thick filament (EMD-2240)([@bib1]) ([Figure 2A](#fig2){ref-type="fig"}). In addition, the predicted SAXS profile of PDB 5TBY is consistent with X-ray solution scattering of squid HMM in Ca^2+^-free (EGTA) conditions ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and the computed scattering profile for the model closely agrees with the measured scattering profile of squid heavy meromyosin (HMM) ([@bib19]). [Figure 2C](#fig2){ref-type="fig"} shows the residuals (relative deviation) between the squid HMM data and the computed 5TBY scattering profile over the range of scattering angles (red line). The χ goodness of fit parameters reported by the FoXS program are 1.5 for 3JBH and 1.85 for 5TBY respectively ([@bib57]). Relative deviation between the 5TBY and 3JBH calculated scattering profiles (dashed line) falls below the noise level of the experimental data (red line) consequently the two models cannot be distinguished. Extending the computations to wider angles (q = 1.0 Å^-1^; see [Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), revealed that the tarantula PDB 3JBH and the human models are essentially identical above q = 0.4 Å^-1^ and unlikely to be distinguished by future SAXS and wide angle X-ray solution scattering experiments in that regime. The SAXS data in this angle range provide support for the overall shape, placement, and orientation of IHM domains.

The PDB 5TBY model also closely matches crystal structures of fragments for human β-cardiac S1 MD fragment (PDB 4DB1) ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"} and [Video 2](#media2){ref-type="other"}) and S2 (PDB 2FXM)([@bib8]) ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} and [Video 3](#media3){ref-type="other"}). Moreover, this model includes important myosin loops that improve the analyses of IHM interactions, and that are absent from the only other IHM model used for cardiac muscle (PDB 3DTP; [@bib4]). In the PDB 5TBY model, the blocked and free myosin heads are in the pre-powerstroke state ([@bib75]; [@bib79]; [@bib43]) and bent at the 'pliant region' ([@bib28]) (see [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"} and [Video 4](#media4){ref-type="other"}). The blocked head is in a pre-powerstroke state ([@bib43]) (similar to the Mg·ADP-AlF~4~, PDB 1BR1; \[[@bib42]; [@bib4]\]) while the free head, which is also in a pre-powerstroke state, shows a less angled lever arm than the blocked head (see [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). In the absence of a human β-cardiac IHM crystal atomic structure, the homologous human β-cardiac myosin IHM model PDB 5TBY ([Figure 2A](#fig2){ref-type="fig"} and [Video 1](#media1){ref-type="other"}) provides a robust option for analyses of cardiomyopathy variants on IHM interactions.Video 2.The motor domain (MD) of the PDB 5TBY model closely matches the crystal structure of a fragment for human β-cardiac S1 MD (PDB 4DB1).The movie shows superimposed MDs of S1s from the PDB 5TBY model and a S1 fragment of PDB 4DB1 (S1 bound to adenylylimidodiphosphate (AMPPNP), a nonhydrolysable analogue of ATP to induce a rigor-like structure, open conformation) as ribbons. The MDs of PDB 5TBY blocked and free heads are in gold and olive respectively while the corresponding fragments from PDB 4DB1 are in brown and magenta. See legend of [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.007](10.7554/eLife.24634.007)10.7554/eLife.24634.007Video 3.The sub-fragment 2 (S2) of the PDB 5TBY IHM model closely matches the crystal structures of S2 for human β-cardiac (PDB 2FXM)([@bib8]).The movie shows the two S2 strands as ribbons of PDB 5TBY in gold and olive (blocked and free heads, respectively) and 2FXM in pink. See legend of [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.008](10.7554/eLife.24634.008)10.7554/eLife.24634.008Video 4.The PDB 5TBY IHM model shows that the blocked and free myosin heads are in the pre-powerstroke state ([@bib79]; [@bib75]; [@bib43]) and bent at the 'pliant region' as defined by [@bib28].The movie shows the free and blocked head structures of PDB 5TBY IHM model as ribbons in gold and olive respectively, versus the pre-powerstroke state PDB 1BR1 crystal structure (magenta). The ELC and RLC were removed to highlight their lever arms, which are in the same plane but have different angles. See legend of [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.009](10.7554/eLife.24634.009)10.7554/eLife.24634.009

Analyses of HCM and DCM variants {#s2-2}
--------------------------------

All sarcomere PVs and LPVs previously identified in 6112 HCM and 1315 DCM cases ([@bib70]) were analyzed. Among HCM cases, 40 *MYH7* PVs substituted 39 distinct aa (two distinct variants encoded an identical substitution) at 33 positions and 95 LPVs led to 95 substitutions at 87 sites ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Thirty-eight PVs altered S1 and S2 residues, and two altered LMM residues. Four further HCM PVs occurred in ELC (n = 2) or RLC (n = 2). Among DCM cases, one *MYH7* PV and 26 LPVs altered 26 distinct aa residues ([Table 3](#tbl3){ref-type="table"}). We considered how these variants impacted residues involved in motor domain functions ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) and in pre-specified IHM interactions ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}).10.7554/eLife.24634.010Table 1.HCM pathogenic variants (PVs) causing 39 *MYH7*, 2 *MYL2*, and 2 *MYL3* amino acid substitutions.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.010](10.7554/eLife.24634.010)SubstitutionLocation\*BH interaction\*Type\*FH interaction\*Type\*Δq^†^Motor Domain Function^‡^***MYH7*Motor Domain**Y115HNear ATP Binding I**+1E170K**Near ATP-binding IId.1Stabilizing**+2R249Q**Near ATP Binding III**-2**I263TNear ATP Binding IV0P307HNear ATP Binding IV**+1R403W/G/L/Q**CM-Loopd.1Stabilizing**-2**Actin interface 1**R442C**Near ATP Binding Vd.1Stabilizing**-2R453C**Near ATP Binding VgPrimingd.1Stabilizing**-2**E483KNear RelayjAnchoringd.2Stabilizing**+2M515T**RelayjAnchoringd.2Stabilizing0Relay**V606M**Helix-loop-helixeStabilizing0Actin interface**R663H**Near Loop 2f.2Priming**-1**M690TSH2 helix0I702NSH1 helix0**G708A**SH1 helix0**G716R**ConverteriAnchoringd.2Stabilizing**+2**ConverterELC-MHCScaffoldingConverter**R719W/Q**Converteri,Anchoringd.2Stabilizing**-2**ConverterELC-MHCScaffoldingConverterR723G/CConverteriAnchoringd.2Stabilizing**-2**ConverterELC-MHCScaffoldingConverter**I736T**ConverterjAnchoringd.2Stabilizing0ConverterELC-MHCScaffoldingConverterG741W / RConverterjAnchoringd.2Stabilizing0 / **+ 2**ConverterELC-MHCScaffoldingConverter**K762R**ConverterjAnchoringd.2Stabilizing**+1**ConverterELC-MHCScaffoldingConverter**K766Q**Converterd.2Stabilizing**-1**Converter**Regulatory Domain**A797TNeck-ELC interfaceELC-MHCScaffoldingELC-MHCScaffolding0F834LHead-tail junctionRLC-MHCScaffoldingRLC-MHCScaffolding0**S2**S842NHead-tail junctionRLC-MHCScaffoldingRLC-MHCScaffolding0R870HKinkgPriminggPriming**-1**D906GRing1f.2Primingf.2Priming**+1**L908VRing1f.2Primingf.2Priming0L915PRing2aStabilizingaStabilizing0E924KRing2aStabilizingaStabilizing**+2**E930KRing2aStabilizingaStabilizing**+2Light Meromyosin**A1379TNear skip 2 residue0R1781CNear skip 4 residue**-2*MYL3*Essential Light Chain**M149VChain FiAnchoringeStabilizing0ELC-MHCScaffoldingH155DChain FiAnchoringELC-MHCScaffolding**-2**ELC-MHCScaffoldingeStabilizing***MYL2*Regulatory Light Chain**E22KNear S15RLC-RLCRegulatingRLC-RLCRegulating**+2**RLC-MHCScaffoldingRLC-MHCScaffoldingR58QChains B-C loopRLC-RLCRegulating**-2**RLC-MHCScaffoldingRLC-MHCScaffolding[^2][^3][^4][^5]10.7554/eLife.24634.011Table 2.HCM likely pathogenic variants (LPVs) causing 95 MYH7 amino acid substitutions.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.011](10.7554/eLife.24634.011)SubstitutionLocation\*BH interaction\*Type\*FH interaction\*Type\*Δq^‡^Motor Domain Function^§^**MYH7Motor DomainR17C**SH3hAnchoring**-2R143Q-2K146N-1R169G/K/S**Near P-loopd.1Stabilizing**−2/--1/−2Q193R**Near P-loop**+2A199V**Near Loop 10**R204C**Loop 1**-2**Actin interface**G214D**Loop 1**-1**Actin interfaceN232HNear Switch 2**+1**D239NSwitch 1**+1**ATP-Binding IIIR243H^†^Switch 1**-1**ATP-Binding IIIF244CSwitch 10ATP-Binding IIIK246INear Switch 1**-1**F247LNear Switch 10I248TNear Switch 10**G256E**Near Switch 1**-1**I263MNear ATP-Binding IV0L267VNear ATP-Binding IV0Y283C0S291FNear I-loop0D309NI-loop**+1**MD-RLC interfaceI323NI-loop0MD-RLC interfaceE328GNear I-loop**+1V338M**0K351ENear C-loop**-2**G354SNear C-loop0E374VC-Loopd.2Stabilizing**+1**Actin interfaceA381DC-Loopd.2Stabilizing**-1**Actin interfaceY386CNear C-loopeStabilizing0**V406M**CM-loopd.1Stabilizing0Actin Interface IY410DCM-loopd.1Stabilizing**-1**Actin Interface IV411ICM-loopd.1Stabilizing0Actin Interface IL427M0**T449S**Near Switch 2gPrimingd.1Stabilizing0**R453S/H**Near Switch 2gPrimingd.1Stabilizing0**/--1**I457TNear Switch 20I478NNear Switch 20N479SNear Switch 20M493V/L/IRelayjAnchoringd.2Stabilizing0Relay**E497G/D**RelayjAnchoringd.2Stabilizing**+1/**0Relay1521TNear Relay0**E536D**H-loopf.2Priming0Actin Interface IIH576RLoop 3**+1**Actin Interface III**G584R**Near Loop 3**+2**V586ANear Loop 30**R652G**Near Loop 2f.2Priming**-2K657Q**Near Loop 2f.2Priming**-1R663C**Near Loop 2f.2Priming**-2**R671CNear SH2 helix**-2R694C/H**SH2 helix**−2/--1P710H/L**Converter**+1**/0Converter**P731A**ConverterjAnchoring0ConverterELC-MHCScaffolding**G733E**ConverterjAnchoringd.2Stabilizing**-1**ConverterELC-MHCScaffolding**R739S**ConverterjAnchoringd.2Stabilizing**-2**ConverterELC-MHCScaffolding**K740N**ConverterjAnchoringd.2Stabilizing**-1**ConverterELC-MHCScaffoldingL749QConverterjAnchoring0ConverterELC-MHCScaffolding**F758C**ConverterjAnchoring0ConverterELC-MHCScaffoldingV763MConverterd.2Stabilizing0Converter**G768R**Converter**+2**Converter**L781P**PliantELC-MHCScaffoldingELC-MHCScaffolding0PivotR783HPliantELC-MHCScaffoldingELC-MHCScaffolding**-1**Pivot**Regulatory Domain**R787CNeck-ELC interfaceELC-MHCScaffoldingELC-MHCScaffolding**-2**A797PNeck-ELC interfaceELC-MHCScaffoldingELC-MHCScaffolding0L811PNeck-ELC-RLC interfaceELC-MHC\
RLC-MHCScaffoldingRLC-MHCScaffolding0**S2**K847EHead-tail junction**-2**E848GHead-tail junction**+1**M849THead-tail junctionA850DHead-tail junction**-1**R858HgPriminggPriming**-1**E894GRing 1f.1Primingf.2Priming**+1**L898VRing 1f.1Primingf.2Priming0A901PRing 1f.1Primingf.2Priming0E903GRing 1f.1Primingf.2Priming**+1**Q914H**+1**D928NRing 2aStabilizingaStabilizing**+1**E929KRing 2aStabilizingaStabilizing**+2**E930QRing 2aStabilizingaStabilizing**+1**E949KRing 3**+2**E967K**+2**R1053Q**-2Light Meromyosin**E1356K**+2**R1382QNear skip 2 residue**-2**L1428S0R1606CNear skip 3 residue**-2**A1763T0R1781HNear skip 4 residue**-1**M1782VNear skip 4 residue[^6][^7][^8][^9][^10]10.7554/eLife.24634.012Table 3.DCM pathogenic variants (PVs) and likely pathogenic variants (LPVs) causing 27 MYH7 amino acid substitutions.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.012](10.7554/eLife.24634.012)SubstitutionLocation^‡^BH interaction^‡^Type^‡^FH interaction^‡^Type^‡^Δq^§^Motor Domain Function^¶^**MYH7Motor DomainG144V**Near ATP Binding I0G178RATP-binding II (P-loop)**+2**ATP Binding IIG181RATP-binding II (P-loop)**+2**ATP Binding II**I201T**Near 25/50 junction (Loop 1)0R243H^†^ATP-binding III (Switch 1)**-1**ATP Binding IIIG245EATP-binding III (Switch 1)**-1**ATP Binding IIII248FNear ATP-binding III0R369QC-Loop (Loop 4)d.2Stabilizing**-2**Actin interfaceD469YATP-binding V (Switch 2)**+1**ATP Binding VI524VNear H-Loopf.2Priming0**E525K**Near H-Loopf.2Priming**+2**I533VH-Loopf.2Priming0Actin interface IIR567HActin-interface III (Loop 3)**-1**Actin interface IIIN597KHelix-loop-helix**+1**Actin interfaceC672FNear SH2 Helix0R783PPliantELC-MHCScaffoldingELC-MHCScaffolding**-2**Pivot**S2**R904C\*/HRing1f.2Primingf.2Priming**−2/--1**E1152V**+1Light Meromyosin**R1193HNear skip 1 residue**-1**E1286K**+2**R1434C**-2**D1450N**+1**R1574W**-2**Q1794E**-1**E1801KNear skip 4 residue**+2**E1914K**+2**.[^11][^12][^13][^14][^15][^16]

### Variants altering functional Motor Domain residues {#s2-2-1}

We compared the distributions of *MYH7* HCM and DCM variants at functional MD residues involved in the nucleotide-binding pocket (39 aa), actin binding (60 aa), converter (68 aa), or relay (27 aa), that together make up 10% of the myosin heavy chain (194 aa; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). *MYH7* variants were not distributed uniformly, but were over-represented at functional MD residues both in HCM (16/40 PVs (40%), 4-fold enrichment above 10% expected, p=6.14e-07; 23/95 LPVs (24%), p=5.11e-05; combined 39/135 (29%), p=7.9e-9; [Tables 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"} and [4](#tbl4){ref-type="table"}) and DCM (7/27 variants (26%), p=0.022; [Tables 3](#tbl3){ref-type="table"} and [5](#tbl5){ref-type="table"}). However these impacted distinct regions. HCM variants were enriched in residues of the converter (n = 21/135 (16%), expected 3.5%, p=1.25e-08; [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}) while 5/27 DCM variants altered nucleotide-binding pocket residues (19%, expected 2.0%, p=0.00019; [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). This supports previous observations that HCM and DCM variants alter distinct functional motor domains ([@bib15]; [@bib61]), leading to altered myocardial contraction ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.24634.013Table 4.The distribution of HCM variants across IHM and MD functional residues.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.013](10.7554/eLife.24634.013)Specified siteVariants within siteRateAmino acids within siteExpected rateRate ratioP-value**IHM Interactions (All)**730.5414470.23102.347.95e-15Priming170.1261130.05842.162.64e-03Anchoring240.1781560.08062.212.11e-04Stabilizing480.3561890.09773.645.37e-16Scaffolding240.1781200.06202.872.97e-06**MD Functional**390.2891940.10002.897.87e-10[^17]10.7554/eLife.24634.014Table 5.The distribution of DCM variants across IHM and MD functional residues.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.014](10.7554/eLife.24634.014)Specified siteVariants within siteRateAmino acids within siteExpected rateRate ratioP-value**IHM Interactions (All)**70.2594470.23101.1200.6550Priming50.1851130.05843.1700.0186Anchoring00.0001560.08060.0000.1650Stabilizing10.0371890.09770.3790.5120Scaffolding10.0371200.06200.5971.0000**MD Functional**70.2592100.10902.3800.0222[^18]

### HCM variants altering IHM interactions {#s2-2-2}

We next defined the distribution of HCM and DCM variants on 447 *MYH7* residues involved in major IHM interactions ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}; [@bib4], [@bib3]). Priming interactions ('f' and 'g', involving 113 aa) dock the blocked head onto its own S2. Anchoring (156 aa) associates the blocked head and ELC to the neighboring myosin tail via interactions 'i', 'h', and 'j'. Stabilizing (189 aa) docks the free head onto the blocked head via interactions 'a', 'd', and 'e'. Scaffolding (120 aa) supports the IHM three-dimensional structure (RLC-MHC and ELC-MHC interactions). Additional RLC-RLC interactions regulate the IHM ([@bib3]). As residues can participate in several interactions, HCM and DCM variants that alter multi-interactive residues can impact formation of the IHM in several ways.

In comparison to expectation, HCM PVs were enriched among the 23% of myosin residues (447 of 1935) involved in the IHM structure, with thirty-one of 40 (78%) *MYH7* PVs altering IHM residues (3.35-fold enrichment; p=5.25e-13; [Table 1](#tbl1){ref-type="table"} [Supplementary file 3a](#SD3-data){ref-type="supplementary-material"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We validated this estimate by analyzing LPVs ([Table 2](#tbl2){ref-type="table"}): Forty-two of 95 LPVs (44%) similarly impacted IHM interactions (1.9-fold enrichment; p=7.04e-06; [Supplementary file 3b](#SD3-data){ref-type="supplementary-material"}). Based on the significant enrichment of HCM variants in residues involved in IHM interactions ([Table 4](#tbl4){ref-type="table"}) we infer that disruption of the IHM contributes to HCM pathophysiology ([Figure 1B](#fig1){ref-type="fig"}).

As cardiomyopathy variants can alter distinct interactions when located on the blocked head versus the free head, we assessed HCM PVs and LPVs exposed to these different environments ([Figure 3A](#fig3){ref-type="fig"} and [Video 5](#media5){ref-type="other"}, [Supplementary file 3f](#SD3-data){ref-type="supplementary-material"}). Thirty-nine of 135 PVs or LPVs alter residues involved in free head interactions (29%, expected 8.8%, p=1.93e-11), 52 altered residues involved in blocked head interactions (39%, expected 19%, p=9.32e-08), and 14 altered residues involved in tail interactions (10%, expected 3.6%, p=3.57e-04). HCM variants that disrupt priming and anchoring residues would prevent the docking of the blocked head to the S2, delaying IHM formation ([Figure 1B](#fig1){ref-type="fig"}, left), while variants that alter stabilizing residues will tend to release the free head from the partner blocked head ([Figure 1B](#fig1){ref-type="fig"}, right). HCM PVs and LPVs ([Supplementary file 3a, b](#SD3-data){ref-type="supplementary-material"}) were particularly enriched in IHM stabilizing interactions (p=5.37e-16 vs. expectation; [Table 4](#tbl4){ref-type="table"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). These 48 variants ([Figure 3](#fig3){ref-type="fig"}, pink) include 11 variants affecting stabilizing residues when located on the blocked head (p=2.01e-2) and 31 variants affecting stabilizing residues when located on the free head (p=2.58e-12). Twenty-four HCM variants ([Figure 3A](#fig3){ref-type="fig"}, orange and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) altered blocked head residues involved in IHM anchoring interactions (p=2.1e-4). Five of eight anchoring variants (involved in 'i' interactions; [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) affect residues that also participate in another IHM interaction ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), we cannot discern whether one or both interactions are more relevant to HCM pathogenesis. HCM variants were only modestly enriched in IHM priming interactions (p=2.6e-3; [Table 4](#tbl4){ref-type="table"}, [Figure 3A](#fig3){ref-type="fig"}, green and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), and affected nine residues on the blocked head and 14 tail residues, including three residues that also participate in stabilizing interactions ([Supplementary file 3d](#SD3-data){ref-type="supplementary-material"}). In addition, 24 *MYH7* variants ([Figure 3A](#fig3){ref-type="fig"}, white; [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}) altered residues that scaffold the MHC and ELC or RLC (p=3.0e-6; [Supplementary file 3d](#SD3-data){ref-type="supplementary-material"}), that were particularly enriched in MHC blocked head residues affecting ELC interactions (p=1.19e-07).10.7554/eLife.24634.015Figure 3.IHM PDB 5TBY models depicting pathogenic (PVs) and likely pathogenic variants (LPVs), in HCM and DCM (listed in [Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"}).Each variant appears as a pair, one located on or associated with the blocked head (BH, olive) and one on the free head (FH, green). Associated proteins are the essential light chain (ELC interacting with BH, brown; FH, purple) and regulatory light chain (RLC interacting with BH, dark blue; FH, light blue). (**A**) HCM PVs and LPVs that alter residues involved in IHM interactions (73/135 variants, 54%) are represented by colored balls: priming, green ('f' and 'g', [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}); anchoring, orange ('i' and 'j', [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}); stabilizing, pink ('a', 'd', and 'e', [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}); scaffolding, white (ELC-MHC and RLC-MHC); RLC-RLC interface, yellow ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). For variants with multiple IHM interactions, only one is depicted. PVs and LPVs that do not alter residues involved in IHM interactions are grey. (**B**) DCM PV and LPV (7/27; 26%) defined here are colored as described above, along with two prior PVs (S532P and F764L, denoted by side chains) that alter IHM interacting residues. Detailed IHM PDB 5TBY models of variants involved in specific interactions are provided in Supplemental Files and [Videos 5](#media5){ref-type="other"} and [6](#media6){ref-type="other"}).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.015](10.7554/eLife.24634.015)10.7554/eLife.24634.016Figure 3---figure supplement 1.Wide-eye stereo pairs of the IHM PDB 5TBY model showing HCM pathogenic variants (**A**) and DCM pathogenic and likely pathogenic variants (**B**).(**A**) IHM PDB 5TBY model mapping 40 HCM pathogenic variants (that produced 39 distinct substitutions in MHC and four substitutions in the regulatory and essential light chains; [Table 1](#tbl1){ref-type="table"}, in the main text) depicted as balls and sticks, with all chains are shown as wires, and the interaction loops highlighted as ribbons. 22/31 PVs (observed 71%, expected 49%, p=0.019) involved on interactions are charge-changing, according to this color code for their Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue). (**B**) IHM PDB 5TBY model mapping 27 DCM-causing variants, showing 26 residues substituted by 27 variants on each head ([Table 3](#tbl3){ref-type="table"}, in the main text) depicted as balls and sticks, with all chains are shown as wires, and the interaction loops highlighted as ribbons. Five of seven (71%) DCM PVs and LPVs involved on interactions are charge-changing, according to this color code for their Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.016](10.7554/eLife.24634.016)10.7554/eLife.24634.017Figure 3---figure supplement 2.Wide-eye stereo pair of the IHM PDB 5TBY model showing the five HCM variants that alter residues involved in IHM priming (intra-molecular interactions 'g' and 'f').Three variants alter resides that participate in 'f' sub-interactions ('f.1': D906G, L908V; 'f.2': R663H) and two alter residues that participate in 'g' interactions (R453C and R870H). All chains are shown as wires, with the interacting loops highlighted as ribbons. Only amino acid substitutions (caused by cardiomyopathy variants) within these interacting loops are highlighted as balls and sticks. The color code reflects the variant's Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.017](10.7554/eLife.24634.017)10.7554/eLife.24634.018Figure 3---figure supplement 3.Wide-eye stereo pair of the IHM PDB 5TBY model showing 13 HCM pathogenic variants involved in anchoring the IHM.Intermolecular interactions between ('j', 'i') myosin and the essential light chain anchor the blocked head anchoring on the neighboring S2. Five substitutions are involved on interaction 'j' between blocked head relay (G483K, M515T) and converter (I736T and G741W/R) with the neighbor S2. Six MHC (G716R, R719W/Q, R723G/C and K762R) variants interact ('i') with the same loop of the blocked head ELC with the neighboring MHC S2. Two substitutions are located on the ELC. All chains are shown as wires, with the interacting loops highlighted as ribbons. Only amino acid substitutions (caused by cardiomyopathy variants) within these interacting loops are highlighted as balls and sticks. The color code reflects the variant's Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.018](10.7554/eLife.24634.018)10.7554/eLife.24634.019Figure 3---figure supplement 4.Wide-eye stereo pair of the IHM PDB 5TBY model showing sites of 25 HCM variants that alter IHM stabilizing residues.Twenty-three MHC variants and two ELC variants alter IHM residues that dock the free head onto the blocked head ('e', 'd' and 'a' interactions). Nineteen *MYH7* substitutions are at residues participating in two 'd' sub-interactions ('d.1': E170K, R403W/G/L/Q, R453C, R442C; 'd.2': G716R, R719W/Q, R723G/C, I736T, G741W/R, E483K, M515T, K762R, K766Q), three substitutions are at 'e' interactions (*MYH7* V606M; *MYL3* M149V and H155D), and three at 'a' interactions (*MYH7* L915P, E924K and E930K). Notably, nine of twelve substitutions involved in sub-interaction "d.2 "alter the charge. All chains are shown as wires, with the interacting loops highlighted as ribbons. Only amino acid substitutions (caused by cardiomyopathy variants) within these interacting loops are highlighted as balls and sticks. The color code reflects the variant's Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.019](10.7554/eLife.24634.019)10.7554/eLife.24634.020Figure 3---figure supplement 5.Wide-eye stereo pair of the IHM PDB 5TBY model showing four variants located in the RLC-RLC interface region.Variants in MHC (S842N and F834L) and RLC (E22K and R58Q) alter residues that allow proper docking of the two opposite surfaces of the RLC-RLC interface when the IHM is initially assembled. The large gray ball denotes phosphorylated Ser15. The small grey yellow denotes the RLC Ca^2+^ pocket. All chains are shown as wires, with the interacting loops highlighted as ribbons. Only amino acid substitutions (caused by cardiomyopathy variants) within these interacting loops are highlighted as balls and sticks. The color code reflects the variant's Δq: −2 (dark red), −1 (pink), 0 (black),+1 (light blue) and +2 (dark blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24634.020](10.7554/eLife.24634.020)10.7554/eLife.24634.021Figure 3---figure supplement 6.Sequence alignment of human cardiac, chicken skeletal and tarantula striated MHC with the locations of HCM variants.Variant positions (arrowheads) are color-coded according their charge-change, as in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.021](10.7554/eLife.24634.021)10.7554/eLife.24634.022Figure 3---figure supplement 7.Sequence alignment of human cardiac, chicken skeletal and tarantula striated MHC with the locations of DCM variants.Variant positions (arrowheads) are color-coded as in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.022](10.7554/eLife.24634.022)10.7554/eLife.24634.023Figure 3---figure supplement 8.Sequence alignment of human cardiac, chicken skeletal and tarantula striated ELC with the locations of HCM variants.HCM variant positions are (arrowheads) color-coded as in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.023](10.7554/eLife.24634.023)10.7554/eLife.24634.024Figure 3---figure supplement 9.Sequence alignment of human cardiac, chicken skeletal and tarantula striated RLC with the location of HCM variants.HCM variant positions are (arrowheads) color-coded as in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.024](10.7554/eLife.24634.024)Video 5.Semi-transparent, space-filled PDB 5TBY IHM structure depicting the impact of HCM variants, when exposed to different IHM environments.HCM variants reside on the myosin blocked head (gold), myosin free head (olive), essential light chain (associated with blocked head (brown) or free head, (purple)), and regulatory light chain (associated with blocked head (dark blue) or free head (blue)). Variants are depicted as balls, colored according to the IHM interactions that are disrupted in each environment: priming, green; anchoring, orange; stabilizing, pink, scaffolding, white and regulatory, yellow. Grey variants alter residues that are not involved in IHM interactions. See legend of [Figure 3A](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.025](10.7554/eLife.24634.025)10.7554/eLife.24634.025

All four HCM PVs in *MYL2* (n = 2) and *MYL3* (n = 2) also affected IHM residues. The *MYL3* variants altered ELC residues involved in anchoring (orange) and scaffolding (white) the blocked head ([Table 1](#tbl1){ref-type="table"} and [Figure 3A](#fig3){ref-type="fig"}), and residues involved in stabilizing (pink) and scaffolding (white) the free head. *MYL2* variants altered residues on the RLC involved in scaffolding ([Figure 3A](#fig3){ref-type="fig"}, white). These variants also altered residues involved in RLC-RLC regulation ([Figure 3A](#fig3){ref-type="fig"}, yellow) of the blocked and free heads.

HCM variants therefore overlie distinct interaction sites when found in the context of the free or blocked head. As the same residue may be involved in more than one interaction, HCM variants have the potential to disrupt multiple IHM properties. Yet while MD and IHM residues overlap, particularly in the converter region, that 73 of 135 *MYH7* PVs and LPVs (54%) alter IHM interaction residues, as do all HCM variants in *MYL2* and *MYL3*, challenges the paradigm that these act primarily through the impairment of myosin motor functions ([@bib53]). As the IHM structure allows myosin to adopt the SRX state, we suggest that HCM PVs and LPVs that perturb dynamic IHM interactions would likely alter physiologic relaxation by the heart, and account for diastolic dysfunction, which is the major component of HCM pathophysiology.

### Distribution of DCM variants on IHM interactions {#s2-2-3}

Parallel analyses of all DCM PVs and LPVs (n = 27) in *MYH7* ([Tables 3](#tbl3){ref-type="table"} and [5](#tbl5){ref-type="table"}, [Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) showed that these were over-represented at MD residues, but were not enriched in residues across all IHM interactions (p=0.65) nor among residues involved in interactions by the blocked head, free head, or tail (p≥0.25). Within specific components of IHM interactions ([Supplementary file 4a, b](#SD4-data){ref-type="supplementary-material"}), five DCM variants altered IHM priming ([Figure 3B](#fig3){ref-type="fig"}, green and [Video 6](#media6){ref-type="other"}), albeit with only nominal significance (p=0.019). Additional DCM variants altered blocked head residues involved in IHM stabilizing interaction (pink) and ELC scaffolding of blocked and free head residues (white), but these were not enriched over expectation. This data show that residues within IHM interaction sites are differentially impacted by variants that cause the distinct pathophysiologies of HCM and DCM.Video 6.Semi-transparent, space-filled PDB 5TBY IHM structure depicting the impact of DCM variants when residing on the myosin blocked head (gold) and myosin free head (olive).Variants are depicted as balls, colored according to the interactions that that disrupt: priming, green; anchoring, orange; stabilizing, pink, and scaffolding, white. Grey variants alter residues that are not involved in IHM interactions. The side chains of two previously reported DCM variants ([@bib56]), S532P and F764L are also colored according to the IHM interaction that these disrupt. See legend of [Figure 3B](#fig3){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.24634.026](10.7554/eLife.24634.026)10.7554/eLife.24634.026

Given the overall limited numbers of myosin DCM PV and LPVs, we also assessed two previously reported DCM *MYH7* PVs, S532P and F764L ([@bib56]) that were not identified in the cardiomyopathy cohort studied here. S532P alters a blocked head residue ([Figure 3B](#fig3){ref-type="fig"}, side chain green), but is not involved in IHM interactions by the free head. F764L alters a blocked head residue that is involved in anchoring and a free head residue involved in IHM stabilization ([Figure 3B](#fig3){ref-type="fig"}, side chain orange and pink, respectively).

A far smaller proportion of myosin DCM PV and LPVs altered residues involved in IHM interactions ([Figure 1C](#fig1){ref-type="fig"}) than HCM variants. Together with the observed enrichment at MD functional domains shown above, this implies that DCM variants predominantly affect myosin MD properties, which is consistent with the predominant clinical manifestations of DCM *MYH7* variants - reduced contractile force but normal diastolic relaxation ([@bib37]).

Charge change by HCM and DCM variants impacts the IHM {#s2-3}
-----------------------------------------------------

An electrostatic charge difference between the wild type and variant residue, Δq, is expected to further destabilize IHM inter- and intra-molecular interactions ([Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"}). Among HCM PVs that alter IHM interacting residues, 22/31 altered the charge (observed 71%, expected 49%, p=0.019): nine (29%) produced charge-gain (+2 \> Δq \> 0) and thirteen (42%) produced charge-loss (−2 \< Δq \< 0).

Charge changing HCM PVs are involved in multiple IHM interactions ([Table 1](#tbl1){ref-type="table"}). Four of five HCM PVs that alter IHM priming residues change the charge, including R870H, which is located on the S2 'kink' resulting in S2 bending which shapes the overall IHM ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, 'g' interaction). Nine of 12 PVs that alter IHM anchoring residues ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, 'i' and 'j') cause a charge change. Nineteen of 24 PVs (79%) change the charge of IHM stabilization residues, particularly those involved in 'd' interactions ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

Both *MYL2* HCM PVs are charge changing and could destabilize MHC-RLC and RLC-RLC interactions ([Figure 3A](#fig3){ref-type="fig"}). *MYL2* R58Q resides in the loop between RLC helices B and C ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}) that form the RLC-RLC interface. Spectroscopic studies of the RLC-RLC interface demonstrate that piperine destabilizes the SRX state, possibly in part by divalent cation binding ([@bib50], [@bib49]). As the E22K variant abolishes RLC phosphorylation and markedly reduces calcium-binding affinity ([@bib67]), while the charge change associated with the R58Q variant would alter helical structures involved in the RLC-RLC interface, both variants should destabilize the SRX state. Consistent with this conclusion, ex vivo analyses of hearts from *MYL2* R58Q transgenic mice demonstrate higher ATPase rates and incomplete relaxation ([@bib21]).

Five of seven (71%) DCM PVs and LPVs affecting IHM interacting residues also have electrostatic charge changes. Variant R904C should make the S2 Ring 1 more negative (−2) and strengthen IHM priming ('f.2') when the blocked head docks onto its S2, therein decreasing ATPase activity. By contrast, a nearby HCM variant (D906G [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) makes the S2 Ring 1 more positive (+1) which weakens IHM priming ('f.2') with resultant increase in expected ATP turnover and numbers of released swaying free heads. Therefore the predicted reciprocal biophysical consequences of adjacent *MYH7* variants on the IHM provide potential mechanisms to explain how nearby, indistinguishable groups variants with opposite charge changes cause the distinct pathophysiology of HCM and DCM ([Figure 1B](#fig1){ref-type="fig"} vs. C).

### HCM variants on the mesa disrupt IHM interactions {#s2-3-1}

The blocked myosin head structure in the IHM is similar to its pre-powerstroke structure ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"} and [Video 4](#media4){ref-type="other"}) that contains a prominent flat myosin surface, denoted as the mesa ([@bib63]; [@bib61]; [@bib26]). The mesa is comprised of 277 aa, of which approximately half are IHM interacting residues. Based on the dynamic IHM structure, we expect that myosin can assume two mesa structures, corresponding to the blocked, docked head and the free head.

Fifty-two of 135 HCM variants (18 PVs and 34 LPVs; p=3.9e-12 versus expected), but only 3 DCM variants (p=0.79), reside on the mesa ([Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"}, [Supplementary file 5](#SD5-data){ref-type="supplementary-material"}, [Figure 4](#fig4){ref-type="fig"} and [Video 7](#media7){ref-type="other"}). Thirty-six HCM variants alter mesa residues that also participate in IHM interactions (4.1-fold above expectation, p=2.38e-13). When located on the blocked head, HCM mesa variants altered residues involved in priming (n = 9), anchoring and scaffolding (n = 15), and stabilizing (n = 6). When located on the free head HCM residues altered IHM stabilization (n = 21) and scaffolding (n = 1). By disrupting blocked S1 head interactions with S2 ('f.1' with S2 Ring 1 and 'g' with the S2 kink; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) that are crucial for establishing SRX, and stabilizing interactions between the blocked and free heads, HCM mesa variants could compromise relaxation and increase free heads available for force potentiation. The model that disruption of the IHM contributes to HCM pathophysiology is therefore entirely compatible with recent data suggesting an important role for the mesa. We expect that variants residing on the mesa ([@bib63]) and that are involved in IHM interactions ([@bib4]; [@bib31]; [@bib44]) may also impact MyBP-C interactions.10.7554/eLife.24634.027Figure 4.The location of 14 variants located on the mesa ([@bib63]; [@bib26]) of the blocked head (BH, olive) and free head (FH, green).The three negatively-charged rings in the blocked head S2 are labeled R1, R2 and R3. The associated sarcomere proteins are depicted as in [Figure 3](#fig3){ref-type="fig"}. The myosin mesas are roughly orthogonal (blocked head mesa, parallel to the page; free head mesa, perpendicular to the page; see [Video 7](#media7){ref-type="other"}). HCM PVs are enriched on the mesa and in IHM interactions when located either on the blocked or free head, suggesting that these disrupt crucial determinants of cardiac relaxation, accounting for diastolic dysfunction in HCM.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.027](10.7554/eLife.24634.027)Video 7.Semi-transparent, space-filled 5TBY IHM structure depicting only HCM variants that reside on the blocked head and free head mesas.The myosin blocked head (gold), myosin free head (olive), essential light chain (associated with blocked head (brown) or free head (purple)), and regulatory light chain (associated with blocked head (dark blue), or free head (blue)) are shown. Mesa variants (numbered according to the amino acid that is altered) are depicted as balls, colored according to the IHM interactions that is disrupted in each environment: priming, green; anchoring, orange; stabilizing, pink, and scaffolding, white. Grey variants alter residues that are not involved in IHM interactions. See legend of [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.24634.028](10.7554/eLife.24634.028)10.7554/eLife.24634.028

Clinical interpretation of rare *MYH7* variants {#s2-4}
-----------------------------------------------

Having identified a relationship between cardiomyopathy variants and residues identified as IHM interaction sites, we considered whether this information improved clinical variant interpretation. We compared the prevalence of all rare (ExAC global allele frequency \<0.0001) missense variants in the 7427 cardiomyopathy subjects ([@bib70]) with 33,364 ancestry-matched ExAC subjects. We calculated disease odds ratios (under the assumption that each individual carries at most one rare variant, since individual-level genotypes are not available in ExAC, see Material and methods) and the etiologic fraction (EF, the proportion of variants in cases that are disease-causing), which represents the probability that a rare variant found on genetic testing in a cardiomyopathy subject is pathogenic (HCM, [Supplementary file 6](#SD6-data){ref-type="supplementary-material"}, DCM, [Supplementary file 7](#SD7-data){ref-type="supplementary-material"}). We calculated these measures for the whole protein, and for pre-specified sub-regions: the myosin head, MD functional sites, the mesa, a previously-described cluster of 29 amino acids in the converter region ([@bib26]), and the IHM interactions described here.

We identified 326 rare (global ExAC allele frequency \<0.0001) variants in 854 of 6112 HCM patients (14%), resulting in 324 distinct aa substitutions at 300 residues. In the ExAC reference sample, 253 rare variants in 449 of 33,364 non-Finnish European subjects (1.4%), resulted in 252 distinct substitutions at 220 residues. Only 50 ExAC variants altered IHM residues (20%, expected 23%, p=0.23) and these were not enriched in specific interactions.

Regional analyses identified portions of the protein that are highly enriched in HCM, yielding a high probability that variants found in HCM patients are causative, with sufficient confidence for clinical application. As expected, these regions include the mesa (EF = 0.98) and MD functional sites (EF = 0.99), particularly the converter domain (EF = 0.99). Interpretive confidence is even higher for certain specific IHM interactions. Notably, rare variants involved in blocked head IHM priming ('g') and stabilizing ('d.1') residues were absent from ExAC but present in 62 HCM cases (p\<e-200), while variants in five other IHM interactions were exceedingly rare in ExAC (EF ≥0.99). These regions accounted for \~44% of variants found in HCM cases (combined prevalence, 6%), but less than 4% of variants in ExAC (combined prevalence, 0.048%), indicating that variants within these sites have extraordinarily high prior probabilities of pathogenicity. Irrespective of our conclusion that these variants act by disrupting IHM interactions, these analyses robustly demonstrate that variants that alter a subset of *MYH7* residues are strongly predictive of HCM and clinically actionable.

Parallel comparisons of 58 rare variants in 68 of 1315 DCM patients (5.2%) indicated that a large proportion of those within the myosin head are pathogenic (EF = 0.75), but that this is insufficient to report novel variants as LPV without additional evidence of pathogenicity. Variants at functional MD residues have a high probability of pathogenicity (EF = 0.96). Among DCM rare variants that altered residues involved in IHM interactions (EF = 0.84), only those that altered IHM priming residues (EF = 0.96) achieved high probabilities of pathogenicity.

Energetic consequences of SRX and DRX states {#s2-5}
--------------------------------------------

Experimental preparations of relaxed cardiac muscles ([@bib27]) display two rates of ATP hydrolysis (slow turnover time, 138--144s; fast turnover time 20 s) that are respectively attributed to docked blocked heads and transiently docked free heads (the SRX state) and swaying free heads in the DRX state ([@bib3]). As such, the proportion of myosin heads in the SRX or DRX state impacts cardiac muscle expenditure of ATP and energy efficiency, parameters that are critical for continuous pumping.

We calculated a theoretical estimate of the populations of relaxed cardiac myosin heads in DRX or SRX (Material and methods) based on the assumptions that (a) the IHM structure accounts for the SRX and that (b) activation of cardiac muscle only impacts free heads in the DRX state while docked blocked heads remain parallel to the thick filament. The latter assumption is supported by fluorescence analyses of RLC in relaxed rat heart fibers, that show both parallel and perpendicular alignment to the thick filament ([@bib33]) and by evidence that cardiac myosin heads remain in the SRX state with tetanic fiber activation ([@bib27]). Based on these assumptions, the asymmetric configuration of myosin heads in the cardiac IHM could yield savings of one ATP molecule when the free head is docked to blocked head (SRX) that would be lost when swaying free heads increase ATP turnover (DRX, [Figure 1A](#fig1){ref-type="fig"}). As such HCM variants in *MYH7, MYL2,* and *MYL3* that impair IHM interactions or that destabilize the RLC-RLC interface ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}) such as occurs with RLC phosphorylation, would reduce SRX:DRX proportions, consume more ATP, and promote free head swaying with potential myosin-actin interactions and force production.

Discussion {#s3}
==========

Biophysical and biochemical analyses of the sarcomere's chemomechanical cycle have defined the molecular basis of force production by striated muscles and illuminated how this is perturbed by cardiomyopathy mutations. Identification of dynamic IHM intra- and inter-molecular interactions that produce populations of relaxed myosins in DRX and SRX states provides additional fundamental insights into sarcomere biology that informs the molecular pathogenesis of HCM and DCM.

We demonstrate that similar proportions of HCM and DCM variants (26--29%) impact myosin residues with MD functions, albeit with distinctly different distributions. DCM variants were enriched only in the nucleotide-binding site (p=0.00019) but were notably absent from the converter domain, a region where residues also function in IHM interactions. By contrast, HCM variants are highly enriched in the converter domain (p=1.25e-8) and on the mesa (p=3.89e-12), domains that both participate in MD functions (HCM variant enrichment, p=7.9e-9) and IHM interactions (HCM variant enrichment, p=7.95e-15). Indeed, HCM variants were 1.19-fold enriched in residues involved only in MD functions, 1.74-fold enriched in residues involved only in IHM interactions, and 4.17-fold enriched in residues that participate in both, providing an account for why HCM PVs and LPVs, unlike DCM variants, have broad effects throughout the contraction and relaxation phases of the cardiac cycle ([Figure 1B](#fig1){ref-type="fig"}).

While the location of HCM variants within functional MD residues of myosin, in vitro motility assays, and single molecule biophysical studies ([@bib69]; [@bib62]; [@bib61]) provide mechanisms for abnormal contractility, these do not account for the prevalent and profound relaxation deficits that characterize HCM. By contrast, evidence that HCM variants in *MYH7, MYL2,* and *MYL3* alter residues that support the dynamic properties of IHM provide mechanisms by which these disrupt cardiac relaxation and energetics ([Figure 1A](#fig1){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}; see Material and methods). HCM variants that impair IHM interactions would reduce SRX:DRX proportion, promote additional myosin-actin interactions, and consume more ATP, resulting in altered relaxation, energetics and force production.

Previous studies of selected cardiomyopathy variants, that employed early thick filament and IHM structures, suggested that these might impact IHM formation ([@bib8]; [@bib4]; [@bib47]). Our study advances these conclusions in several ways. Capitalizing on a novel human β-cardiac myosin IHM PDB 5TBY structure we considered if cardiomyopathy residues altered specific IHM interactions. Second, we studied a comprehensive and unselected set of PVs and LPVs that were independently identified in a large cardiomyopathy cohort (7427 HCM and DCM patients) and compared these to variants in 33,370 ExAC controls. We found that only HCM variants were significantly enriched in many IHM interacting residues, most notably in those that stabilize the IHM (p=5.37e-16 vs. expectation). As most HCM variants resulted in a charge change ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), these are expected to adversely affect IHM interactions. Taken together, these data provide strong support that HCM variants perturb cardiac relaxation by disrupting IHM interactions. A corollary to this conclusion is that the IHM interacting residues identified by the PDB 5TBY structure are physiologically valid.

We recognize several limitations in our analyses. First, there are neither atomic nor near-atomic structures of the human cardiac IHM. Although a near-atomic (0.6 nm) structure of the *Lethocerus* thick filament backbone has been reported ([@bib29]), the resolution for the IHM is comparable (2.0 nm) to the tarantula structure employed here, perhaps because the intrinsic flexibility of swaying free heads limits higher resolution ([@bib9]; [@bib65]). Second, using homologous *MYH7* sequences, we converted the tarantula (PDB 3JBH) into a human (PDB 5TBY) IHM model, which fits well into the human beta-cardiac 3D-reconstruction ([Figure 2a](#fig2){ref-type="fig"}). While capitalizing on the high evolutionary conservation between human MYH7 and tarantula striated myosin (60% amino acid identity), especially residues involved in IHM interactions ([@bib3]), we expect that future models will refine the resolution of interactions identified in the PDB 5TBY model. Third, the tarantula striated muscle lacks MyBP-C and titin, molecules that may interact with IHMs to form helices that protrude from vertebrate thick filaments and limit interactions between myosin heads and actin ([@bib4]; [@bib31]; [@bib44]). The locations of several HCM variants hint that these may have additional functional consequences that impair interactions between consecutive IHMs. Fourth, while our data support the conclusion that the structural states defined by the IHM are responsible for the DRX and SRX functional states, these cannot be proven to be synonymous.

We also expect that high-resolution human cardiac thick filament structures will extend these insights to other HCM genes and variants. MyBP-C harbors many HCM variants that reduce protein levels ([@bib24]) and evoke functional consequences similar to MyBP-C phosphorylation: increase calcium sensitivity of active force and acceleration of rigor force and rigor stiffness development ([@bib36]). The C1C2 fragment of MyBP-C ([@bib23]) is predicted to interact with the second of three negatively charged rings ([@bib8]) on the myosin S2 domain ([Figure 2A](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}, labeled as R1-3), and Ring 2 residues participate in stabilizing the IHM. Charge inverting (+2) variants on Ring 2 (E924K and E930K in [Table 1](#tbl1){ref-type="table"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"} 'a'; E927K and E935K, described in ([@bib8]) could disrupt MyBP-C binding ([@bib39]), and destabilize the IHM, as would HCM variants that deplete MyBP-C protein levels. Moreover, destabilization of the IHM could account for the significant reduction of SRX that occurs in mice lacking MyBP-C ([@bib46]). With the enrichment of *MYH7* variants in IHM interacting residues reported here, we suggest that altered physiologic ratios of SRX and DRX populations is the mechanism by which HCM disrupts cardiac relaxation.

Integrated consequences of cardiomyopathy variants on myocardial physiology {#s3-1}
---------------------------------------------------------------------------

HCM and DCM are dominant disorders and sarcomeres contain an admixture of normal and mutated myosin proteins. As *MYH7* DCM variants primarily impact functional MD residues (e.g. nucleotide binding and hydrolysis), these will depress contractility in proportion to the summed force produced by myosins with and without variants ([@bib56]; [@bib61]), with concurrent reduction in ATP consumption. The resultant under-performance of sarcomeres containing DCM variants promotes compensatory ventricular dilation (Frank-Starling mechanism) to maintain circulatory demands ([Figure 1C](#fig1){ref-type="fig"}).

By contrast, ([@bib56]; [@bib61]) HCM variants impact both MD functions and IHM properties. Any pair of myosins involved in asymmetric IHM interactions may contain zero, one, or two mutated residues with singular or dual consequences when located on the blocked or free head ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}). The 135 HCM PVs and LPVs described here will alter 39 functional MD residues on each head and 73 IHM interacting residues, located on the blocked or free heads or S2 domain ([Supplementary file 3f](#SD3-data){ref-type="supplementary-material"}). Notably, 41 of these 135 variants altered only one IHM interaction, while 32 altered residues involved in at least two interactions simultaneously, typically a different one for each head ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). We suggest that the effects of HCM variants on contractility, their consequences on MD functions, and the multiple effects on IHM interactions, confers a complexity that can explain the dissimilar results obtained when myosin mutations are studied in the context of single myosin molecules that only assess MD functions and myofibril experiments that also interrogate the IHM ([@bib47]). For example, R453C can simultaneously affect IHM priming ('g' interaction) when located on the blocked head ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) and stabilization ('d.1') when on the free head ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Biomechanical assays of myosin R453C shows decreased actin-sliding velocity and ATPase, but increased force production ([@bib60]). These dichotomous results may be explained by the IHM paradigm ([Figures 1B](#fig1){ref-type="fig"} and [3A](#fig3){ref-type="fig"}). Located near the switch 2 with the nucleotide-binding pocket, R453C would impair S1 functions that are assayed by single molecule in vitro analyses. When located on the blocked head ('g', [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) the charge change of R453C (Δq = −2) would destabilize blocked myosin heads and increase the number of heads (the released blocked head and the associated partner free heads) that are available for force potentiation. As such, the increase in sarcomere force observed with many HCM variants likely reflects the combined effect on MD functions and IHM interactions that increase myosin populations in DRX and reduce those in SRX states.

HCM variants will further impact cardiac physiology because of the relationship between the proportion of myosins in the DRX and SRX states and energy consumption ([Figure 1B](#fig1){ref-type="fig"}). Swaying free myosin heads in the DRX state consume 5-fold greater ATP than in the SRX state ([@bib27]), and physiologic SRX:DRX levels during relaxation may reduce energy consumption and support life-long continuous activity. By disrupting IHM interactions, HCM variants would reciprocally increase the proportion of myosins in the DRX state and decreased the proportion in the SRX state -- resulting in increased ATP consumption and metabolic demands, yielding energy deficiencies that characterize human HCM hearts ([@bib7]). These observations also provide a plausible mechanistic explanation for why MYK-461, an ATPase inhibitor, improved the pathophysiology in HCM mouse models ([@bib20]).

In summary, the integrated interpretation of HCM and DCM variants on myosin MD functions and dynamic IHM interactions provides a fuller understanding of sarcomere biology in health and disease. While DCM variants evoke primary deficits in MD functions ([Figure 1C](#fig1){ref-type="fig"}), HCM variants perturb both MD functions and IHM interactions ([Figure 1B](#fig1){ref-type="fig"}). By disrupting IHM priming, anchoring, stability, and scaffolding interactions, HCM variants decrease populations of docked myosin heads (SRX) and increase swaying heads (DRX) that are available for force production, thereby promoting hypercontractility. The reduction of myosin populations in SRX would perturb diastolic relaxation and increase ATP consumption, causing energy deficiencies in HCM hearts ([@bib7]). Notably, these are primary biophysical deficits produced directly by HCM variants that are unrelated to secondary compensatory changes observed in other heart diseases. Clinical observations support this conclusion: hyperdynamic contraction, diastolic dysfunction ([@bib25]), and energy deficiency ([@bib32]; [@bib14]) precedes hypertrophic remodeling in young HCM variant mutation carriers. We conclude that the identification of sarcomere protein residues involved in relaxation provide new opportunities to target the IHM to improve HCM pathophysiology and other heart diseases with diastolic dysfunction. By extension of these analyses to skeletal myopathies we anticipate further insights into critical roles of the highly conserved IHM in the relaxation of striated muscles.

Material and methods {#s4}
====================

Overview {#s4-1}
--------

We first generated a new homologous human β-cardiac myosin IHM quasi-atomic model, and used this to identify residues at sites of IHM interactions. These interaction sites were predefined from structural models, without prior knowledge of the location or distributions of HCM or DCM variants. We then examined the locations of a large series of clinically defined cardiomyopathy variants ([@bib70]). All these independently classified HCM and DCM PVs or LPVs were included in our statistical analyses. Finally, for predefined *MYH7* functional regions we compared the total prevalence rare variants (not stratified by clinical consequence) in cardiomyopathy cases and a reference population to derive unbiased and quantitative estimates of clinical interpretability. Code to reproduce statistical analyses (in R) and figures (in Chimera) is available on GitHub ([@bib71]).

Myosin II MHC, ELC and RLC sequences {#s4-2}
------------------------------------

Sequences include human β-cardiac MHC (P12883), ELC (P08590) and RLC (P10916); chicken skeletal muscle MHC (P13538) and tarantula (*Aphonopelma sp.*) skeletal muscle ELC (GenBank KT390185), RLC (PDB KT390186) ([@bib78]) and MHC (GenBank KT619079) ([@bib3]). Alignments of the human β-cardiac, chicken skeletal and tarantula striated MHC, ELC and RLC that are shown in [Figure 3---figure supplements 6](#fig3s6){ref-type="fig"}--[9](#fig3s9){ref-type="fig"} were generated with Clustal ([@bib38]) over the JalView platform ([@bib72]).

Homology modeling and rigid docking {#s4-3}
-----------------------------------

Human β-cardiac myosin ELC, RLC and MHC (MD and S2) were modeled as described ([@bib3]). The human β-cardiac myosin interacting-heads motif ([Figure 2A](#fig2){ref-type="fig"} and [Video 1](#media1){ref-type="other"}) has been deposited into the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB 5TBY). A rigid fitting of this model was done against the human cardiac negatively stained thick filament 2.8 nm resolution 3D-reconstruction (EMD-2240) ([@bib1]) using the Chimera 'Fit in Map' option ([Figure 2A](#fig2){ref-type="fig"} and [Video 1](#media1){ref-type="other"}) ([@bib51]).

SAXS analysis {#s4-4}
-------------

Sample preparation and data collection details for squid HMM are previously reported ([@bib19]). Scattering intensity, I(q), is in arbitrary units, with q = 4π sin(θ)/λ in units of Å^−1^. The wavelength λ = 1.2563 Å and the scattering angle is 2θ as measured from the direct beam. Scattering profiles for PDB 5TBY and tarantula PDB 3JBH were computed using both FoXS ([@bib57]) and CRYSOL ([@bib66]) to compare agreement, especially at scattering angles q \> 0.3 Å^-1^. As described previously, CRYSOL required more than the default number of harmonics ([@bib66]) for agreement with FoXS in the WAXS regime and the algorithms agreed on the location and magnitude of the difference between the PDB models despite a minor baseline shift (not shown). Currently neither of these methods model flexibility, an effect that could also introduce baseline shifts at wider angles. The FoXS calculations reported here fit both the computed profiles to the squid HMM experimental data using the default parameters of hydration layer, excluded volume, and background adjustment ([@bib19]). In the case of [Figure 2B,C](#fig2){ref-type="fig"} the 'profile offset' optimization was performed to obtain best fit with the data at widest angles ([@bib57]). The goodness of fit parameter χ, reported by FoXS, is defined as$$\chi = \sqrt{\frac{1}{M}\sum\limits_{i = 1}^{M}\left( \frac{I_{exp}(q_{i}) - I(q_{i})}{\sigma(q_{i})} \right)^{2}},$$

where $I_{exp}(q_{i})$ is the experimental scattering profile measured at M points $(q_{i})$ with error given by $\sigma(q_{i})$ Model profiles, $I(q_{i})$, that agree with the data to within expected noise levels give χ values close to unity. ([@bib19]; [@bib57]; [@bib66])

Identification of IHM interaction sites {#s4-5}
---------------------------------------

The analysis of the interactions was done as described ([@bib3]), using the 'Protein interfaces, surfaces and assemblies' (PISA) service at the European Bioinformatics Institute (<http://www.ebi.ac.uk/pdbe/prot_int/pistart.html>) ([@bib35]). Interactions were described as intra- or inter-molecular according to the customary convention used in IHM studies ([@bib74]; [@bib3]).

Accession numbers {#s4-6}
-----------------

The atomic coordinates of the human β-cardiac myosin IHM quasi-atomic model have been deposited into the Research Collaborators for Structural Bioinformatics as PDB entry 5TBY.

Curation of HCM and DCM variants {#s4-7}
--------------------------------

Variants found in samples from 7427 individuals referred for genetic testing with a referral diagnosis of HCM or DCM, sequenced in accredited diagnostic laboratories with clinical-grade variant interpretation (3826 individuals sequenced at Oxford Medical Genetics Laboratories ([@bib70]), and 3668 individuals from the Partners HealthCare Laboratory of Molecular Medicine ([@bib52]; [@bib5]) were used in our analysis. In total, 6112 HCM patients had *MYH7* sequencing, including 4185 also with *MYL2* and *MYL3* sequencing, while 1315 DCM cases had *MYH7* sequencing and 543 DCM also with *MYL2* and *MYL3* sequencing. First, all curated variants reported as pathogenic by either laboratory (HCM PV, [Table 1](#tbl1){ref-type="table"}) were assessed in the mapping analyses ([Figure 3A](#fig3){ref-type="fig"}, [Supplementary file 3a](#SD3-data){ref-type="supplementary-material"}, [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[5](#fig3s5){ref-type="fig"}). Variants reported as likely pathogenic (HCM LPV, [Table 2](#tbl2){ref-type="table"}, [Supplementary file 3b](#SD3-data){ref-type="supplementary-material"}, [Figure 3A](#fig3){ref-type="fig"}) were then analyzed for replication. Subsequent analyses of specific interactions include HCM PVs and LPVs combined ([Table 4](#tbl4){ref-type="table"}, [Supplementary file 3a-d](#SD3-data){ref-type="supplementary-material"}). Given the smaller number of variants in DCM, and that PV and LPV behaved similarly in HCM, all DCM PV and LPV were considered together ([Tables 3](#tbl3){ref-type="table"} and [5](#tbl5){ref-type="table"}, [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}, [Figure 3B](#fig3){ref-type="fig"}).

Assessing the regional distribution of variants {#s4-8}
-----------------------------------------------

To determine whether variants were over-represented in a region of interest ([Supplementary files 1](#SD1-data){ref-type="supplementary-material"}, [2](#SD2-data){ref-type="supplementary-material"}), the proportion of variants ([Supplementary files 3](#SD3-data){ref-type="supplementary-material"}--[5](#SD5-data){ref-type="supplementary-material"}) that fell within the region was compared with the proportion that would be expected under a uniform distribution (given by the length of the region / total protein length). Proportions were compared using a binomial test, implemented in R ([@bib71]).

*MYH7* variants in the general population {#s4-9}
-----------------------------------------

In order to confirm the importance of the pre-specified IHM interaction sites ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}), and to determine the strength of the disease association for variants at different sites, we compared the total prevalence of rare variants in the case series described above (irrespective of clinical laboratory classification) with the prevalence amongst reference samples from the Exome Aggregation Consortium (ExAC; [@bib40]); [Supplementary files 6](#SD6-data){ref-type="supplementary-material"}, [7](#SD7-data){ref-type="supplementary-material"}). Rare (ExAC global AF \<0.0001) missense variants were extracted from the ExAC vcf (version 0.3.1). Analysis was restricted to the ExAC sub-population of European ancestry, as the case series is drawn from a predominantly Caucasian background ([@bib70]). The median number of ExAC samples genotyped at each variant site was used as the ExAC population size (33,364), and prevalence was compared using the binomial test ([@bib71]). A disease odds ratio (OR) was estimated (under the assumption that each rare variant was found in a distinct individual), and the etiological fraction (EF) was calculated as (OR -- 1)/OR ([@bib71]). The EF, a commonly used method in epidemiology, estimates the proportion of affected variant carriers in which the variant caused the disease, which can also be interpreted as the probability that an individual rare variant, found in a proband, is responsible for the disease ([@bib22]; [@bib55]; [@bib11]; [@bib70]).

Mapping of the MHC, ELC and RLC HCM and DCM variants to the human β-cardiac myosin IHM structure PDB 5TBY {#s4-10}
---------------------------------------------------------------------------------------------------------

The sites of 43 curated HCM aa substitutions ([Table 1](#tbl1){ref-type="table"}), 95 LPV substitutions ([Table 2](#tbl2){ref-type="table"}), and 27 DCM aa substitutions (PVs plus LPVs, [Table 3](#tbl3){ref-type="table"}) are shown in [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[5](#fig3s5){ref-type="fig"}. UCSF Chimera software version 10.2 ([@bib51]) was used to build [Figures 2A](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[5](#fig3s5){ref-type="fig"}. The Chimera sessions (.py) used for making [Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[5](#fig3s5){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} are available in GitHub ([@bib71]). A copy is archived at <https://github.com/elifesciences-publications/eLife_Alamo2017>.

Assessment of charge changes {#s4-11}
----------------------------

In order to determine what proportion of missense changes might be expected to be charge-changing, we determined all possible single nucleotide variant events for MYH7 (1935 codons x nine possible SNV codon changes = 17,415 events). For 12,850 possible missense substitution events, we then determined the charge change: 2681 would lead to a negative charge change, 3604 to a positive charge change, and 6565 would be charge neutral, yielding an expectation that 49% of missense substitutions might be charge changing.

Estimates of SRX and DRX populations in relaxed skeletal and cardiac muscle {#s4-12}
---------------------------------------------------------------------------

### Relaxed skeletal muscle {#s4-12-1}

The proportion of skeletal muscle myosins in the SRX or DRX states has been deduced from the population of heads parallel or perpendicular to the filament axis, using fluorescence polarization from bifunctional rhodamine probes bound to the RLC. In relaxed rabbit psoas muscle, approximately 70% of all myosin heads are parallel to the fiber axis, while \~30% of all myosin heads are perpendicular ([@bib17]), implying that the head population comprises 50% blocked heads that are all parallel, 20% docked free heads that are parallel and 30% swaying free heads that are perpendicular. According to the relaxed IHM state model for skeletal muscle ([@bib3]), the blocked head remains docked while the free head sways away for a time t~s~ and is docked only for a time t~d~. Therefore for a total time t = t~s~ + t~d~, the swaying duty cycle D~s~ is defined as the ratio t~s~/t. D~s~ can be estimated in the relaxed skeletal muscles from measurements of the RLC orientation using fluorescence polarization from bifunctional rhodamine probes bound to the skeletal RLC and cardiac RLC (Fusi et al., 2015) ([@bib33]). In relaxed demembranated rabbit psoas muscle \~70% of the heads have their RLC orientation roughly parallel to the fiber axis, similar to those in the IHM structure, while the RLC orientation of the remainder \~30% of heads is more perpendicular, which is inconsistent with the IHM structure (Fusi et al., 2015). For the estimation of D~s~ and the SRX/DRX ratio we assume a population of N myosin molecules, so as each myosin molecule has one free (FH) and one blocked (BH) head, the sub-populations of free (N~FH~) and blocked (N~BH~) heads sum N~BH~ + N~FH~ = 2N. The populations of heads measured in the parallel conformation is N~par~ = N~BH-par~ + N~FH-par~, while the populations of heads measured in the perpendicular conformation is N~per~ = N~BH-per~ + N~FH-per~. In the relaxed state, blocked heads are docked so N~BH-per~ = 0, therefore N~per~ = N~FH-per~. As a result the number of heads in the perpendicular conformation N~per~ = N~FH-per~ = (t~s~/t)N~FH~ = D~s~N~FH~ = D~s~N while the number of free heads in the parallel conformation is N~FH-par~ = N~FH~ - N~FH-per~ = N~FH~ - (t~s~/t)N~FH~ = N~FH~ -D~s~N~FH~ = (1-D~s~)N. Therefore the number of heads in the parallel conformation is N~par~ = N~BH-par~ + N~FH-par~ = N~BH-par~+ (1 - D~s~)N, and as N~BH-par~ = N because blocked heads are docked in the relaxed state, then N~par~ = (2-D~s~)N; in contrast the number of heads in the perpendicular conformation is N~per~ = D~s~N. Therefore the relative number of heads in the parallel and perpendicular conformations are respectively N~par~/2N = (2 - D~s~)N/2N = (2- D~s~)/2 and N~per~/2N = D~s~N/2N = D~s~/2. Finally the ratio R of heads in the parallel and perpendicular conformation is R= N~par~/N~per~= (2-D~s~)/D~s~ so we conclude that D~s~ = 2/(1+R). Therefore in skeletal muscle R = 0.70/0.3 = 2.3 so D~s~ = 0.60. Assuming that FHs spend 60% of the cycle released and swaying, and 40% docked on the blocked head the estimated ratio of skeletal muscle heads in the SRX and DRX states is SRX/DRX = (2 -- D~s~)/D~s~ = 2.3, predicting an estimated 2.3-fold reduction of ATP hydrolysis. As skeletal muscle myosin heads rapidly transition out of SRX into DRX, such as occurs with tetanic activation ([@bib27]) ([@bib9]), the changing population of myosin SRX and DRX heads in skeletal muscle achieves energy-saving imposed by the IHM structure but retains the ability to rapidly shift myosin into DRX for force potentiation.

### Relaxed cardiac muscle {#s4-12-2}

Assessment of the population of cardiac myosin heads based on parallel or perpendicular alignment to the filament axis is more complicated because fluorescence analyses of RLC in relaxed ventricular fibers from rat hearts show both orientations ([@bib33]). However, because previous studies show that cardiac myosin heads remain in the SRX state with tetanic fiber activation ([@bib27]), we deduced that activation of cardiac muscle only impacts free heads in the DRX state; docked blocked heads in the SRX state are not recruited. Supporting this idea, there is rapid re-ordering and presumably re-forming of the IHM following cardiac contraction, a finding that suggests that the IHM must be regenerated during the relaxation phase that follows every heartbeat ([@bib30]) ([@bib77]). Based on the assumption that IHM and SRX states are one and the same in cardiac muscle, we calculated the corresponding D~s~ and SRX/DRX ratios from the fluorescent analysis results of ([@bib33]) that showed both parallel and perpendicular orientations. By further assuming that the myosin parallel and perpendicular populations are roughly similar, a conservative estimate of cardiac D~s~ is 80% and the SRX/DRX ratio is 1.5. This conservative estimate of Ds = 0.8 was considerable higher than skeletal muscle, that is, most free heads are not interacting with the blocked head, with a smaller SRX/DRX of 1.5. Based on these observations, we suggest that cardiac IHM swaying duty cycle D~s~ should be considerable higher than skeletal muscle, that is, most free heads are not interacting with the blocked head. With these assumptions, the asymmetric configuration of myosin heads in the cardiac IHM would yield savings of one ATP molecule when the free head is docked to blocked head (SRX) that would be lost when swaying free heads increase ATP turnover (DRX, [Figure 1A](#fig1){ref-type="fig"}). Moreover, HCM variants in *MYH7, MYL2,* and *MYL3* that impair IHM regulating interactions, like phosphorylation-dependent destabilization of the RLC-RLC interface ([Figure 3---figure supplement 7](#fig3s7){ref-type="fig"}) would reduce SRX:DRX proportions and consume more ATP and promote additional myosin-actin interactions and force.
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Decision letter

Robbins

Jeffrey

Reviewing editor

Cincinnati Children\'s Hospital Medical Center, University of Cincinnati

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Effect of Myosin Variants on Interacting-Heads Motif Explain Distinct Hypertrophic and Dilated Cardiomyopathy Phenotypes\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Harry Dietz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Sharlene Day (Reviewer \#1); Anne Houdusse (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. In general, all reviewers and the Reviewing Editor found the study very interesting but some concerns were raised that need to be resolved. With important modifications, in particular by recognizing the limits of the current knowledge of the interactions in the IHM and the difficulties and inherent limitations of evaluating how a single mutation can impact interactions and function, the article will be of interest for people in the field since there has not been a global description of how the current model of the IHM interactions can result in HCM or DCM disease.

Summary:

In an attempt to understand the functional consequences of different hypertrophic and dilated cardiomyopathy mutations in human cardiac β myosin heavy chain, the manuscript integrates data from protein modeling using a quasi-atomic model, mutations found in the patient population and protein-protein interactions of the head region in an attempt to establish mechanistic bases for structure-function. Major conclusions are reached concerning the structural pathogenesis of the hypertrophic and dilated cardiomyopathy mutations utilizing a large cardiomyopathy database comprised of 7,427 individuals. The authors use a low resolution model of the interacting heads motif that was previously published to globally identify which residues mutated in these diseases are involved in stabilization interactions. The data show that the hypertrophic and dilated cardiomyopathic variants differentially affect the motor domain and interacting heads motif of the protein, potentially informing the mechanistic interpretations of how the different mutations influence sarcomeric function and power development at the molecular level.

Essential revisions:

1\) A major concern on the part of multiple reviewers was that the relatively low resolution of the published data, and the paucity of rigorously defined interactive residues are not commensurate with the \"definite\" tone taken by the authors at multiple places in the manuscript when stating their conclusions. That is, there is too much emphasis throughout the manuscript on trying to establish dogma and generalize conclusions. For example, in paragraph three of the Discussion section, the authors speculate that mutations in titin and MYBPC3 could also impact IHM properties and alter relaxation. The majority of mutations in these 2 genes are truncating mutations that are hypothesized to act primarily by loss of function. And since the residues in MYBPC3 and titin that interact with S2 are not known, it\'s difficult to predict which missense variants would affect these interactions. Proposing that disruption of IHM formation or stability is a common mechanism for mutations in all thick filament genes for HCM seems to be a bit of a leap. It is not clear from the current paragraph, subsection "HCM variants implicated in MyBP-C binding disrupt IHM interactions", whether the authors here mostly report on what has been previously proposed or whether they have themselves performed a study that agrees with previous reports. In particular, they should report whether the EM model can provide a proposition on the residues likely involved in interaction with MyBP-C and if it is restricted to the second charged ring on the S2. In fact, the impact of MyBP-C on the IHM should also be considered. While cMyBP-C may stabilize the IHM (Zhogbi, Woodhead, Moss and Craig, 2008) and SRX state (McNamara, et al., 2016) the sites of interaction are still highly debated. The structure proposed by Alamo et al. is based on a small subset of contacts in the literature and highly speculative at best. The authors might consider removing this section to avoid further confusion.

The reviewers raise the very legitimate question as to why, in previous manuscripts, the authors state that their previous models didn\'t have the resolution needed to draw such conclusions. What has led to their changing their minds? In the absence of a convincing argument that addresses this concern, they have simply used a large database to formulate hypotheses that now can be rigorously tested. The limitations of the work presented in this manuscript need to be clearly and explicitly stated in the Discussion.

2\) Alamo et al. state \"Although there is limited resolution of the cardiac interconnecting inter-molecular interactions between sequential IHMs along the helices of myosin heads protruding from the thick filament backbone, we note that 12 HCM PVs and LPVs are also positioned to alter inter-IHM interactions data not shown) and limit swaying free heads from actin interactions.\" Can the authors clarify what they believe the resolution to be for these inter-IHM and intra-IHM interactions? Would the inter- and intra-IHM contacts be affected by the fact that the tarantula striated muscle IHM quasi-atomic cryo-EM structure comes from a thick filament with a 4 start helix while the human cardiac thick filament is a 3 start helix?

3\) The manuscript makes the assumption that IHM first observed in smooth muscle and then in tarantula muscle is the structural state responsible for the SRX kinetic state first described by Cooke, 2011, in skeletal and then cardiac muscles. While I realize this assumption may be correct, can the authors point to clear experimental evidence showing that IHM and SRX states are one and the same in cardiac muscle as it pertains to the literature?

4\) SAXS and model ([Figure 2B](#fig2){ref-type="fig"}): The authors compare theoretical scattering curves from their homology model and experimental scattering curve from squid HMM (subsection "Comparisons of the human β-cardiac myosin IHM quasi-atomic PDB 5TBY with existing models"). In order to better compare the two curves, the authors should provide a χ2 and residual curves (resulting from the comparison of the two scattering curves). The authors do not demonstrate with this comparison whether different possible models that could be built within the EM map would be distinguished. The limitation of the model for defining precisely the contact regions within the IHM should be discussed further. The sentence "Although resolution of the IHM structure as derived by cryo-EM does not define specific atomic contacts or individual side chain densities, this model nonetheless identifies molecular interactions.", is too ambiguous to indicate how confident one can be on the position of various regions that the authors describe as being involved in IHM contacts. For example, what is really known about what forms the RLC/RLC interface (subsection "Charge Change by HCM and DCM variants Impacts the IHM" third paragraph, on MYL2 R58Q)? Is there sufficient resolution to indicate which residues form the interface between these two side chains?

5\) The mutations studied here are not clearly identified from the figures and tables. The statistics mentioned in the text (for example subsection "HCM variants altering IHM interactions") cannot always allow the identification of the specific mutations they correspond to -- as an example, in paragraph three: which are the five of eight variants involved in\'i\' interactions that affect residues that also participate in another IHM interaction? The authors should better introduce how the mutations were classified, which mutations belong with which category -- rather than providing% on whether or not they belong to a particular subclass. This could be improved possibly by the figure legend of the table and a clearer reference to the table in which the residues beyond these numbers are presented. It seems important also to describe how many mutations do not fit in these conclusions to evaluate the limits of the prediction this study can provide.

6\) Energetic consequences of SRX and DRX states: This part of the result doesn\'t really exploit much of the authors\' model or mutations. It is not clear what the authors are trying to add here that has not been discussed in previous publications or would be relevant with what is presented above. In any case, for the demonstration/calculations/ definition of Ds, the authors should explicitly say that all the parameters and calculations are based on an assumption: the blocked head remains in a parallel configuration and that only SRX or DRX configurations of the myosin is possible (one head blocked / the other one freely able to dock or stay free).

The authors should provide substantial support for this important assumption that the blocked head always stays in the parallel configuration. In any case, this model doesn\'t seem appropriate here when mutations that would destabilize the blocked head are considered.

All the parameters introduced here do not really make a point relevant about DCM or HCM mutations that justify their Introduction in the paper, as currently written.

10.7554/eLife.24634.039

Author response

*Essential revisions:*

*1) A major concern on the part of multiple reviewers was that the relatively low resolution of the published data, and the paucity of rigorously defined interactive residues are not commensurate with the \"definite\" tone taken by the authors at multiple places in the manuscript when stating their conclusions.*

The reviewer comments bring out an important potential source of confusion that we have attempted to clarify in the revised manuscript. While the quasi-atomic model presented here, PDB 5TBY, is consistent with existing low-resolution structural data, its strength lies in the multiple lines of additional evidence that justify the appropriateness of the physiologically important IHM interactions studied here:

1\) There is substantial evolutionary conservation between human β cardiac myosin and striated myosin from the tarantula (60% amino acid identity), especially among residues involved in IHM interactions (Alamo et al., 2016).

2\) The PDB 5TBY model fits well to the 28Å resolution 3D-reconstruction for the negatively stained human cardiac thick filament (EMD-2240) (Al-Khayat et al., 2013) and closely matches crystal structures of fragments for human β-cardiac S1 motor domain (PDB 4DB1) and S2 fragments (PDB 2FXM) reported by Blankenfeldt and colleagues (Blankenfeldt et al., 2006).

3\) Most importantly, we remind the reviewers that the IHM interacting residues reported in Alamo et al. (Alamo et al., 2016) were independently predefined without knowledge of the human genetic variants reported by Walsh et al., 2016, that were classified by clinical laboratories. We also considered all reported variants (both pathogenic and likely pathogenic) identified in HCM, DCM, and those within the general population in this study. To clarify this we have added an overview to the Materials and methods that states:

"These interaction sites were predefined from structural models (see Supplemental Information), without prior knowledge of the location or distributions of HCM or DCM variants. We then examined the locations of a large series of clinically defined cardiomyopathy variants (Walsh et al., 2016). All these independently classified HCM and DCM PVs or LPVs were included in our statistical analyses."

Predicated on these elements we provide a comprehensive approach that demonstrates:

a\) IHM interacting residues are strongly and specifically enriched for HCM-associated variants. We show that this enrichment is independently significant for pathogenic and likely pathogenic HCM variants, providing both initial and replicated observations. As the prototypic clinical manifestations of HCM are closely aligned with the predicted functional consequences of altering IHM structures, we are confident that this association reflects cause and effect.

b\) The location of interacting residues improves the discrimination of pathogenic HCM variants from benign variants.

c\) That IHM interacting residues are NOT enriched for DCM variants nor variants found in the general population. If the replicated HCM finding were spurious, we would have seen a signal in these other variant datasets.

Even with our confidence in these results, in this revision we provide readers with statements to alert them that the model is not perfect, and we specify limitations in the Discussion. In the Results, we introduce the model with a disclaimer that states:

"The IHM structure as derived by cryo-EM does not define specific atomic contacts or individual side chain densities"

In the Discussion we have added a paragraph that specifies limitations of our analyses.

"We recognize several limitations in our analyses ....."

Including that "....we expect that future models will refine the resolution of interactions identified

*That is, there is too much emphasis throughout the manuscript on trying to establish dogma and generalize conclusions. For example, in paragraph three of the Discussion section, the authors speculate that mutations in titin and MYBPC3 could also impact IHM properties and alter relaxation. The majority of mutations in these 2 genes are truncating mutations that are hypothesized to act primarily by loss of function. And since the residues in MYBPC3 and titin that interact with S2 are not known, it\'s difficult to predict which missense variants would affect these interactions. Proposing that disruption of IHM formation or stability is a common mechanism for mutations in all thick filament genes for HCM seems to be a bit of a leap. It is not clear from the current paragraph, subsection "HCM variants implicated in MyBP-C binding disrupt IHM interactions", whether the authors here mostly report on what has been previously proposed or whether they have themselves performed a study that agrees with previous reports. In particular, they should report whether the EM model can provide a proposition on the residues likely involved in interaction with MyBP-C and if it is restricted to the second charged ring on the S2. In fact, the impact of MyBP-C on the IHM should also be considered. While cMyBP-C may stabilize the IHM (Zhogbi, Woodhead, Moss and Craig, 2008) and SRX state (McNamara, 2016) the sites of interaction are still highly debated. The structure proposed by Alamo et al. is based on a small subset of contacts in the literature and highly speculative at best. The authors might consider removing this section to avoid further confusion.*

We have revised the entire text to provide specific rather than general conclusions. We agree that our data does not define specifically identify interactions involved in MYPBC3 interactions, and as recommended we have removed this section from the Results. However, because prior publications implicate MyBPC interactions with three negative rings on the myosin S2, the discussion includes a speculation that MyBPC3 variants could abrogate these interactions and destabilize the IHM, with adverse effects on SRX (subsection "Energetic Consequences of SRX and DRX States"). This speculation is supported by published studies that demonstrate biochemical evidence for reduced SRX in *MYBPC3*- null mice (McNamara et al., 2016).

*The reviewers raise the very legitimate question as to why, in previous manuscripts, the authors state that their previous models didn\'t have the resolution needed to draw such conclusions. What has led to their changing their minds? In the absence of a convincing argument that addresses this concern, they have simply used a large database to formulate hypotheses that now can be rigorously tested. The limitations of the work presented in this manuscript need to be clearly and explicitly stated in the Discussion.*

Our comments on the "resolution of the model" are addressed above. The most compelling reason for our "change of mind" is that human genetics now provides an independent strategy that validates these interactions. That only HCM variants are selectively enriched in IHM interactions (unlike variants in DCM patients or in the general population) and that most HCM variants alter the charge of the encoded residue provides complementary supportive information. We explicitly state this in the Discussion section:

"Taken together, these data provide strong support that HCM variants perturb cardiac relaxation by disrupting IHM interactions. A corollary to this conclusion is that the IHM interacting residues identified by the PDB 5TBY structure are physiologically valid."

As requested, we have added a detailed limitation section to the Discussion (paragraph five).

*2) Alamo et al. state \"Although there is limited resolution of the cardiac interconnecting inter-molecular interactions between sequential IHMs along the helices of myosin heads protruding from the thick filament backbone, we note that 12 HCM PVs and LPVs are also positioned to alter inter-IHM interactions data not shown) and limit swaying free heads from actin interactions.\" Can the authors clarify what they believe the resolution to be for these inter-IHM and intra-IHM interactions? Would the inter- and intra-IHM contacts be affected by the fact that the tarantula striated muscle IHM quasi-atomic cryo-EM structure comes from a thick filament with a 4 start helix while the human cardiac thick filament is a 3 start helix?*

We elected to delete this paragraph, which was not central to our analyses or conclusions. However, for the interest of the reviewers we provide the follow explanation. The tarantula thick filament is perfectly helical and has 4 helices of IHMs on the backbone surface. On each helix, there are adjacent IHMs (with intermolecular interactions \"b\" and \"c\") that are spaced every 14.5 nm producing a \"crown\", of IHMs that are rotated by 30 degrees, from the prior crown, so that three crowns occur every 43.5 nm. In tarantula thick filaments, the IHMs on each of these three crowns are equivalent (making a 43.5 nm repeat) that interact through intermolecular interactions \"b\" and \"c\" (described in Alamo, et al., 2016). The initial text stated "we note that 12 HCM PVs and LPVs are also positioned to alter inter-IHM interactions" because these variants impact \"b\" and \"c\" interactions.

*3) The manuscript makes the assumption that IHM first observed in smooth muscle and then in tarantula muscle is the structural state responsible for the SRX kinetic state first described by Cooke, 2011in skeletal and then cardiac muscles. While I realize this assumption may be correct, can the authors point to clear experimental evidence showing that IHM and SRX states are one and the same in cardiac muscle as it pertains to the literature?*

We are not aware of any experimental evidence that definitely shows that IHM and SRX states are one. Indeed, we expect that new technologies would need to be developed to simultaneously assess structure (e.g. IHM interactions) and function (e.g., ATP cycling). While cryo-EM may be able to provide multiple structural states that differ in conformation within a single specimen this only provides the structural correlate of kinetic states -- and cannot directly prove that a structure equals a functional state.

To remind the reader of these issues, we have modified the text to indicate we assume the IHM structure accounts for the SRX as follows:

"We calculated a theoretical estimate of the populations of relaxed cardiac myosin heads in DRX or SRX (Supplemental Information) based on the assumptions that a) the IHM structure accounts for the SRX and that....."

"Fourth, while our data support the conclusion that the structural states defined by the IHM are responsible for the DRX and SRX functional states, these cannot be proven to be synonymous. "

*4) SAXS and model ([Figure 2B](#fig2){ref-type="fig"}): The authors compare theoretical scattering curves from their homology model and experimental scattering curve from squid HMM (subsection "Comparisons of the human β-cardiac myosin IHM quasi-atomic PDB 5TBY with existing models"). In order to better compare the two curves, the authors should provide a χ2 and residual curves (resulting from the comparison of the two scattering curves).*

As requested by the reviewer, the SAXS curve in [Figure 2B](#fig2){ref-type="fig"} has been revised to include an additional panel (2C) showing the relative deviation of the predicted scatter of 5TBY from the experimental squid HMM data. Additionally, we have provided a dashed line showing the relative deviation between the two models, 5TBY and 3JBH on the same scale for comparison. The legend of [Figure 2](#fig2){ref-type="fig"} has been updated, adding the new part, 2C. A corresponding comment in the Results now states: "The "χ" goodness of fit parameters reported by the FoXS program are 1.5 for 3JBH and 1.85 for 5TBY respectively (Schneidman-Duhovny et al., 2013). Relative deviation between the 5TBY and 3JBH calculated scattering profiles (dashed line) falls below the noise level of the experimental data (red line), and consequently the two models cannot be distinguished. "

Quality of fit parameters "χ" as reported by the FoXS software have been included in the Results. It should be noted that it has become customary in the SAXS literature to report χ rather than χ2. The two are related in the obvious way, and we have added the formula and a reference in the Material and Methods section.

*The authors do not demonstrate with this comparison whether different possible models that could be built within the EM map would be distinguished.*

The aim of this comparison was only to show that the human cardiac IHM PDB 5TBY quasi-atomic model fit the only available IHM experimental SAXS profile (for squid) not comparing the predicted SAXS profiles of different human cardiac IHM models that could be built as we only have this one.

*The limitation of the model for defining precisely the contact regions within the IHM should be discussed further. The sentence "Although resolution of the IHM structure as derived by cryo-EM does not define specific atomic contacts or individual side chain densities, this model nonetheless identifies molecular interactions.", is too ambiguous to indicate how confident one can be on the position of various regions that the authors describe as being involved in IHM contacts. For example, what is really known about what forms the RLC/RLC interface (subsection "Charge Change by HCM and DCM variants Impacts the IHM" third paragraph, on MYL2 R58Q)? Is there sufficient resolution to indicate which residues form the interface between these two side chains?*

Please see responses to comment \#1. As indicated above, we now provide limitations in the Discussion.

5\) The mutations studied here are not clearly identified from the figures and tables.

We apologize for this confusion. To address this we have done the following:

1\) Edited the text to indicate that all variants reported by Walsh and colleagues were studied.

"All sarcomere PVs and LPVs previously identified in 6112 HCM and 1315 DCM cases (Walsh et al., 2016) were analyzed."

2\) Added details to the Materials and methods:

"We then examined the locations of a large series of clinically defined cardiomyopathy variants (Walsh et al., 2016). All these independently classified HCM and DCM PVs or LPVs were included in our statistical analyses."

3\) Provided [Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"} as part into the main text, as these tables report the specific variants and charge change, variant locations in motor domains and IHM interactions when the variant is located on the blocked or free head.

Walsh and colleagues (Walsh et al., 2016) used standard clinical criteria to classify pathogenic and likely pathogenic variants in HCM and DCM patients. We did not reiterate the details in this published manuscript, but provide an overview in Materials and methods (subsection "Curation of HCM and DCM variants").

*The statistics mentioned in the text (for example subsection "HCM variants altering IHM interactions") cannot always allow the identification of the specific mutations they correspond to -- as an example, in paragraph three: which are the five of eight variants involved in\'i\' interactions that affect residues that also participate in another IHM interaction? The authors should better introduce how the mutations were classified, which mutations belong with which category -- rather than providing% on whether or not they belong to a particular subclass.*

We apologize for the confusion. Throughout the manuscript, statistical analyses are provided for all IHM interactions, and when specifically noted, for specified IHM interactions, to highlight interactions that are particularly enriched for HCM variants. In this revision we provide a summary table for HCM ([Table 4](#tbl4){ref-type="table"}) and DCM ([Table 5](#tbl5){ref-type="table"}) that describe statistical enrichment for all variants across the IHM and for major specific interactions, so that readers can readily access these essential data. In addition to presenting statistical summaries, we have also added to the legend a reference to the source table, where the full listing and annotations for the variants included in that particular analysis.

We apologize for our intended meaning was unclear. The revised text has clarified this sentence.

"Twenty-four HCM variants ([Figure 3A](#fig3){ref-type="fig"}, orange and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) altered blocked head residues involved in IHM anchoring interactions (p=2.1e-4). Five of eight anchoring variants (involved in "i" interactions; [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) affect residues that also participate in another IHM interaction ([Tables 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}) we cannot discern whether one or both interactions are more relevant to HCM pathogenesis. "

*This could be improved possibly by the figure legend of the table and a clearer reference to the table in which the residues beyond these numbers are presented. It seems important also to describe how many mutations do not fit in these conclusions to evaluate the limits of the prediction this study can provide.*

As indicated above, our conclusions are based analyses of all HCM and DCM PVs and LPVs that were identified in 6112 HCM and 1315 DCM cases (Walsh, 2016 \#48). No variants were excluded from any analyses reported here. We have modified the legends for [Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"} to indicate this. Furthermore, for each table presenting statistical summaries we have added to the legend a reference to the source table listing the variants included in that particular analysis.

*6) Energetic consequences of SRX and DRX states: This part of the result doesn\'t really exploit much of the authors\' model or mutations. It is not clear what the authors are trying to add here that has not been discussed in previous publications or would be relevant with what is presented above. In any case, for the demonstration/calculations/ definition of Ds, the authors should explicitly say that all the parameters and calculations are based on an assumption: the blocked head remains in a parallel configuration and that only SRX or DRX configurations of the myosin is possible (one head blocked / the other one freely able to dock or stay free).*

*All the parameters introduced here do not really make a point relevant about DCM or HCM mutations that justify their Introduction in the paper, as currently written.*

We agree that the original section of energetic consequences is predicated on multiple assumptions and for cardiac muscle represents a theoretic calculation. However we respectfully disagree that these data are irrelevant to HCM and DCM variants. As indicated in the text HCM variants are known to cause increased energy requirements (Ashrafian et al., 2011). This is one of three central disease components (along with hypercontractility and impaired relaxation) that has been heretofore unexplained.

To balance these issues, we have substantially modified the text as follows. The manuscript now contains a brief overview of energetic consequences that occur by altering IHM interactions (starting in paragraph two of subsection "HCM variants on the mesa disrupt IHM interactions") and populations of myosins in SRX or DRX. The Supplemental Information provides details on the assumptions, specific parameters, and all calculations used to estimate these populations, and how varying population sizes relates to energy consumption.

*The authors should provide substantial support for this important assumption that the blocked head always stays in the parallel configuration. In any case, this model doesn\'t seem appropriate here when mutations that would destabilize the blocked head are considered.*

The energetics section in the Supplemental Information specifically address this:

"However, because previous studies show that cardiac myosin heads remain in the SRX state with tetanic fiber activation (Hooijman et al., 2011), we deduced that activation of cardiac muscle only impacts free heads in the DRX state; docked blocked heads in the SRX state are not recruited. Supporting this idea, there is rapid re-ordering and presumably re-forming of the IHM following cardiac contraction, a finding that suggests that the IHM must be regenerated during the relaxation phase that follows every heartbeat (Huxley et al., 1982) (Yuan et al., 2015) \[...\] By further assuming that the myosin parallel and perpendicular populations are roughly similar \[...\]"

[^1]: These authors contributed equally to this work.

[^2]: All PVs identified in 6112 HCM patients ([@bib70]) are shown. In *MYH7* there are 40 PVs, leading to 39 distinct substitutions at 33 positions while in *MYL2* and *MYL3* there are four more pathogenic variants. HCM PVs located on the mesa are bolded.

[^3]: \*[Supplementary file 1](#SD1-data){ref-type="supplementary-material"} defines domain locations and [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} defines IHM interactions, refined using the PISA analysis ([@bib35]) that are highlighted as in [Figure 3](#fig3){ref-type="fig"}, excluding the two LMM substitutions. RLC--RLC denotes interface region between regulatory light chains.

[^4]: ^†^Δq: variant induced electrical charge change. Δq defines whether the substituted amino acid changes the charge (bolded) or not (Δq = 0).

[^5]: ^‡^Motor domain functions are ascribed only to variants within involved residues. RLC--RLC denotes interface region between regulatory light chains. Variants at IHM interactions sites are colored according to the interaction affected: priming = green, anchoring = orange, stabilizing = pink, scaffolding = white, regulating = yellow.

[^6]: All LPVs identified in 6112 HCM patients ([@bib70]) are shown. In MYH7 there 95 LPVs, leading to 95 distinct amino acid substitutions at 87 positions.

[^7]: \*[Supplementary file 1](#SD1-data){ref-type="supplementary-material"} defines domain locations and [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} defines IHM interactions, refined using the PISA analysis ([@bib35]) that are highlighted as in [Figure 3](#fig3){ref-type="fig"}, excluding the LMM variants. HCM LPVs located on the mesa are bolded.

[^8]: ^†^R243H was identified in both HCM and DCM cohorts. RLC--RLC denotes interface region between regulatory light chains.

[^9]: ^‡^Δq: variant induced electrical charge change. Δq defines whether the substituted amino acid changes the charge (bolded) or not (Δq = 0).

[^10]: ^§^Motor domain functions are ascribed only to variants within involved residues. Variants at IHM interactions sites are colored according to the interaction affected: priming = green, anchoring = orange, stabilizing = pink, scaffolding = white.

[^11]: All PVs and LPVs identified in 1315 DCM patients ([@bib70]) are shown. In *MYH7* there are 27 DCM pathogenic and likely pathogenic variants, leading to 27 distinct substitutions at 26 residues. DCM LPVs located on the mesa are bolded.

[^12]: \*R904C is the only DCM PV.

[^13]: ^†^R243H was identified in both HCM and DCM cohorts. In this cohort, no variants in *MYL2* or *MYL3* caused DCM.

[^14]: ^‡^[Supplementary file 1](#SD2-data){ref-type="supplementary-material"} defines domain locations and [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} defines IHM interactions, refined using the PISA analysis ([@bib35]) that are highlighted as in [Figure 3](#fig3){ref-type="fig"}, excluding the LMM variants.

[^15]: ^§^Δq: variant induced electrical charge change. Δq defines whether the substituted amino acid changes the charge (bolded) or not (Δq = 0).

[^16]: ^¶^Motor domain functions are ascribed only to variants within involved residues. Variants at IHM interactions sites are colored according to the interaction affected: priming = green, stabilizing = pink, scaffolding = white.

[^17]: The numbers of distinct pathogenic and likely pathogenic HCM variants (n = 135) affecting IHM interaction sites and motor domain (MD) functional residues are shown. Variant numbers are also tabulated separately for the four major IHM interactions: priming, anchoring, stabilizing and scaffolding. Note that a single variant may impact more than one interaction. The number of myosin amino acid residues (total protein length = 1935 residues) that compromise the IHM interaction sites or MD functions was used to determine the proportion of variants that would be expected to lie in the region of interest under the null (a uniform distribution), and the rates are compared with a binomial test. Full details of all variants are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}.

[^18]: The numbers of distinct pathogenic and likely pathogenic DCM variants (n = 27) affecting IHM interactions and motor domain (MD) functional residues are shown. Variant numbers are also tabulated separately for the four major IHM interactions: priming, anchoring, stabilizing and scaffolding. Note that a single variant may impact more than one interaction. The number of myosin amino acid residues (total protein length = 1935 residues) that compromise the IHM interaction sites or MD functions was used to determine the proportion of variants that would be expected to lie in the region of interest under the null (a uniform distribution), and the rates are compared with a binomial test. Full details of all variants are shown in [Table 3](#tbl3){ref-type="table"}.
